Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 1 of 126Clinical Study Protocol
Drug Substance AZD 4635 
Study Code D8731C00001
Version 8.0
Date 28 September, 2022
An Open-label, Multi-drug, Multi-center Phase II Combination Study of 
AZD4635 in Patients with Prostate Cancer
Sponsor: [COMPANY_008] AB, 151 85 S√∂dert√§lje, SwedenRedacted 
da
edAnAnOpenOpen -lab
D4635 in PaD4635 in P
ZenecaZeneca Afor B,,1515
Public 
Disclosure
./, %*%"!4 ('*'" (401#34,+/+"+(4 
44
	
4
4 +,%4('*'" )4/2$34-+0+"+)4

	
#56+32=	==#47#1 #5=	=
)=1g3THGSa?L;g/=,L;1Zga1V1g ?KUG1K1L[10g3TVg[=?Zg,K1L0K1N[g
f#!7+32=

=<2346+6= _U0,[10g[=1g?L8ML,[?SNg,N0g[1MODLSHS;cgS2g[=1g ([_0cg=,?V
#56+32=	=	=<=	=
)=1g8HHSa?L;g/=,L;1Zga1V1g?KUH1K1N\10g8Vg [=?Zg,K1L0K1N[g
f#!7+32=

=<2346+6=_U0,[10g[=1g@L3TMP,[?SNgS2g [=1g(^_0cg=,?V
f#!7+32=

=<2346+6=,K1N010g[Sg/H,V?:g \=,[g4YSKg?KUH 1K1N[,[?SNgS2gG?L?/,Hg ([_0c
#VS[S/SGg(#g `1VZ?SNgg[=1gSL]W,/\g&1Z1,V/=g "V;,N?e,[?SNg [=-[ga?HHg[,F1g S`1Vg[=1
K,L,;1K1L[gS2g\=1gU,[?1N[Zga?HHg.1g #,V1b1H
f#!7+32== #2#'75+6-= 66#661#27=_U0,[10g?01N[@3B10gV?ZFZg8Vg*g,ZgU1V
!L`1Z[?;,[SVZgVS/ =_V1g!
f#!7+32=

=2"=3%= 679"<="#'2+7+32= ,0010g[=1g0,[1gS2gUV@K,dg,L-HcZ?Zg 0-[-g/_[S6
"	
f#!7+32==5#71#27=&7#5=7*#=#2"=3&=7*#=679"<= ,K1L010g[Sg/H,V ?2cg_L01Vga=?/=
/SN0?[?SNZgU,[?1L\Zg /,Ng/SN[DL_1g[SgV1/1?`1g[=1gZ[_0cg\W1,\K1N[
f#!7+32=
=&$8<="7=73= #= !30/#!7#"=(//3;+2)=7*#= 45+15<==3&=7*#
679"<=,K1L010g[Sg/H,V?:g[=,[gS`1V0SZ1g,L0g UV1<,L/cga?IHgZ[?HHg.1gV1USV[10g ,HSL;
a@[=g(Zg,2[1Wg"
f#!7+32=

=#4358+2)= 3%=6#5+396= ":#56#=#:#276=#!8,32=
=5#)22!<
X1KS`10g,HHgV15V1N/1Zg[Sg(Zg,N0g UV1;N,N/cgX1USA?L;g [Sg(,V,=g,RSN
1`1GS[LOCATION_006]1N[g!QLS`,[?SLZ
LS`,[?SLZg('	g (g,N0gUV1<,N/cgV1USA?L;g a@HGg.1
=,L0H10g.cg[=1g01Z@;L,\10gZ[V,*1L 1/,gV1UV1Z1L[,^?`1Z
f#!7+32=

=#435 7+2)=3%=6#5+396= ":#56#=#:#276=#!7+32=
= 5#)22!<
#!7+32=
 =:#5"36#=,K1N010g[Sg/H,V?:g[=,[g(Zg UV1;L,N/?1Zg,L0gS`1V0SZ1Z
a?HGg.1gV1USA10g_Z?L;gU,U1Vg 3TMPZg3TVgU,[?1L[Zg[=,^g/SL\?N_1g[V1,[K1L[g,91Vg [=1g"
0,[1g,N0g,0010g[=1g0,[1	
f#!7+32==77+67+!.=326+"#57+326= ,K1L010g[Sg/H,V?:g\=,[g 3CL,Hg,L,GcZ?ZgS2g,HH
1N0US?N[ZgZU1/?3C10gDLg[=?ZgUWS[S/SGga?HHg_Z1g,HGg0,[,g_Ug\Sg,L0g@L/H_0?N;g[=1g0,[1gS2
7L,Hg,N,HcZ?Zg"	
f 1L1V,Hg,0K?L@Z[V,[?`1g /=,L;1ZgK,01g\=WS_;=S_\g3TVg/SLZ?Z[1L/cg?Ng [=1g(#
#56+32=	=
=92#=	
=
 GS.,Hg/=,L;1ZgZ[V?F1[=VS_;>g?L0?/,[1Zg01H1\10g [1b[g
f#!7+32=

=<2346+6=([_0cg=,?Vg,K1L010g[Sg/H-W?:[=,[+$ ?Zg\=1g
L1agZ[_0cg/=,?V	
f#!7+32== /#!753!5"+3)516= ,K1L010g\Sg/J-W?:g[=,[g8Vg,HHg Zg01\,?HZgS2
V=c\=Kg#&g&&g%&(g,N0g%)gEL\1W`,HZg,N0g,Lg S`1V,HGg1`,H_,[?SNg a?HHg.1gV1/SV010g
	
44 4 4+&44
./, %*%"!4 ('*'" (401#34,+/+"+(4 
44
	
4
4 +,%4('*'" )4/2$34-+0+"+)4
./#,+7
77.2.67 7
-!$.0-$.9(90"9 4(090"09 0"9*-0$$+(09 ".90$4&795%0"-5(9
)(.(090)90"9*-)..$(!9)90"$-9*-.)(&9090"94$0&9.0 02.9)90"9
*-0$$+(09 (99 )0$(979 .$09*-.)((&9-)'9*3&$&794$&&9
-/)2-.95"-9$09$.9*)..$& 90)9)9.)9 2(-9**&$&9 &)&9&5.9
c0$,+77 06707XKd+0d-KGG0-X0/d5GHK^=J9dX;0d OPBI(ad!dK2dX;0dTVY/a
<(Ud,11Jd(//1/dWLdW<1dOPKWL.LDd
c0$,+7
700$/1$'7,+/$.0$,+/7 (I1J/1/dWLd.D(P>8d X<(Wd(d.KIOQ1<1JU>]1
UW(W>UW>.(Dd(J(DaU>UdOE(Jd_>DDd,1d/1] 1DLO1/d(J/d4@J(D>b1/d,14MP1d/(W(,(U1dEK.Cd(J/d_>ED
/1U.P>,1dW<1dO(W>1JWdOLOZD(W>LJUdWKd,1d>J.DZ/1/d?Jd X<1d(J(DaU1Ud  )-'97
.0-(9 ()-99 0"$-9*-189(J/dOPK.1/ZP1Ud4NQd(..LZJX?J:d4MPd I>UUAJ:
ZJZU1/d(J/dUOZR>LZUd/(W(
c0$,+7
7+76+,-/$/7 (I1J/1/dWLd.E)P>8dW<(Wd **-)6$'0&79
dO(W>1JXUd_>DE
<(]1d#$%dI1(UZP(,D1d/?U1(U1d (Wd,(U1DAJ1d>Jd1(.<dIL/ZD1
c0$,+7
7 ,-2(0$,+7!.7 +'6//7<(Ud,11JdP1]>U1/d(J/dJK_d>J.DZ/1UdLU1/
O(W>1JWUd_>W<d(WdD1(UWddR1OLPW(,D1d "d.LJ.1JXP(W>LJd//>W>LJ( DEad"d(J(DaU>U
:Z>/1D>J1Ud<)]1d,11JdP1]>U1/
c0$,+7
	7 %+$0$,+7,7 +7,$+0/7<(Ud,11JdP1]>U1/dWKd>J.DZ/1d/ZR](EZI(,d (J/
LD1.EZI(,d"d.LJ.1JWP(W>LJU
c0$,+7
	7 5-,/2.7<(Ud,11JdZ
c0$,+7
	7<(Ud,11JdP1]>U1/
./$,+7	7
7 3+77
DL,(Ed.<(J:1Ud
c//?X>KJdK3d L/[D1dd' d>Jd.LI,AJ*X?LJd_>W<d/ZP](EZI(,d(J /dLE1.DZI(,
OO1J/?`d 
c&O/(W1/d.LP1dOPLWL.KDdXLd >J.DZ/1d L/ZD1dd	'dAJd.LI,>J(W> LJd_>W<
/ZP](DZI(,d(J/dLF1.DZI(,dOO1J/>`d d_<>.<dI(adOPL.11/dO1Pd$OLJULRd/?U.P1W>LJ
(J/dP1]>1_dL3d L/ZE1d d/(W(
c0$,+77 6+,-/$/7+7 '770$,+7	7)$+$'7 /.+$+"7-., 2./7+
0$,+77  %67////*+0/7 ZO/(W1/dXLd.D(P>8d &&9*0$(0.9-9,090)9"4
)0"9
 	
9(9)(9.(.909# 9."2& 9$..9 ....'(0
c0$,+77 6+,-/$/7+70#,+77&0$4/7 +7+-,$+0/7(I1J/1/dWKd.D)P>8
W<(WdIZDW>OD1dUZII(Q>1Ud6LIdW<1d(d(J
 1>1Pd.ZQ]1d_>DDd,1dP1d LPW1/d4MQdP(/>KDLd >.(D
PLdP1UU>KJ
711dU\S]>](Ed
44 4 	4+&44
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 8 of 126Changes to the protocol are summarized b elow in response to comments from the FDA 
received on the 20thMay 2019.
!Section 5.2 Exclusion criteria:
oUpdating of exclusion criteria 2 from ‚Äú History of seizures, CNS tumors or 
metastasis‚Äù to ‚ÄúPreviously untreated brain metastases. Patients who have received radiation or surgery for brain metastases are eligible if therapy was completed at least 21 days previously and there is no evidence of CNS disease progression or mild neurologic symptoms ‚Äù;
oRemoval of exclusion criteria 6: ‚Äú Symptoms of a significant mental illness in 
the 4-week period preceding drug administration ‚Äù.
!Section 4.3 Justification f or dose: updated to add su mmary of food effect data.Version 2.0, [ADDRESS_277496] procedures. The Clinical Study Protocol is publicly registered and the results are disclosed and/or published according to the [COMPANY_008] Global Policy on Bioethics and in 
compliance with prevailing laws and regulations.oUpdated exclusion criterion [ADDRESS_277497] dose of study drug for chemotherapy: ‚â•21 days or 5 
half-lives (whichever is shorter longer) of the first dose of study drug.
!Section 8.1 Efficacy assessments was updated to clarify: All CT/bone scans and all 
imaging assessments performed for RECIST 1.[ADDRESS_277498] 1.1 review, if deemed appropriate. More information on 
this procedure is available in the Image Acquisition Guideline for this study.Version 3.0, 01 July 2019
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 9 of 126TABLE OF CONTENTS
TITLE PAGE ........................................................................................................................ 1
VERSION HISTORY ........................................................................................................... 2
TABLE OF CONTENTS ....................................................................................................... 9
1 PROTOCOL SUMMARY ................................................................................ 14
1.1 Synopsis ............................................................................................................ 14
1.2 Schema ............................................................................................................. 181.3 Schedule of Activities (SoA) - Screening........................................................... 19
2 INTRODUCTION ............................................................................................ 21
2.1 Study rationale .................................................................................................. 21
2.2 Background ....................................................................................................... 22
2.3 Benefit/risk assessment ..................................................................................... 23
3 OBJECTIVES AND ENDPOINTS ................................................................... 24
4 STUDY DESI GN ............................................................................................. 26
4.1 Overall design................................................................................................... 26
4.1.1 Modular protocol structure ................................................................................ 27
[IP_ADDRESS] List of modu les ................................................................................................. 28
4.1.2 Clinical screening procedures ............................................................................ 28
4.1.3 COVID-19 testing (if app licable) ....................................................................... 29
4.2 Scientific rationale for study design................................................................... 304.3 Justification for AZD4635 dose ......................................................................... 30
4.4 End of study definition...................................................................................... 31
5 STUDY POPULATION .................................................................................... 32
5.1 Inclusion criteria ............................................................................................... 32
5.2 Exclusion criteria .............................................................................................. 34
5.3 Lifestyle restrictions .......................................................................................... 38
5.3.1 Meals and dietary restr ictions ............................................................................ 38
5.3.2 Re production ..................................................................................................... 38
5.4 Screen failures................................................................................................... 39
6 STUDY TREATM ENTS .................................................................................. 40
6.1 Treatments adminis tered.................................................................................... 40
6.1.1 Investigational products .................................................................................... 40
6.2 Preparation/handling/storage/accountability ....................................................... 41
6.3 Measures to minimize bias ................................................................................ 41
6.4 Treatment comp liance ....................................................................................... 42
6.5 Treatment assignment ........................................................................................ 43
6.5.1 Methods for assigning treatment groups ............................................................ 43
6.5.2 Procedures for handling incorrectly allocated p atients ....................................... 43
Clinical Study Protocol ‚Äì 8.[ADDRESS_277499] v1.1.............................................................. 51
8.1.2 PCWG3 bone lesions assessment ...................................................................... 53
8.1.4 PWCG3 PSA
criteria ......................................................................................... 54
8.2 Safety assessments ............................................................................................ 54
8.2.1 Clinical safety laboratory assessments ............................................................... 54
8.2.2 Physical ex aminations ....................................................................................... 57
8.2.3 Performance s tatus ............................................................................................ 57
8.2.4 Vital signs ......................................................................................................... 58
8.2.5 El ectrocardiograms ............................................................................................ 58
8.2.6 Echocardiography or multi-ga ted acquisition scan ............................................. 59
8.2.7 End-of-treatm ent visit........................................................................................ 59
8.2.8 Follow-up vi sits ................................................................................................ 59
[IP_ADDRESS] 30-day follow- up visit ....................................................................................... 59
[IP_ADDRESS] Progression-free follow-up visits ....................................................................... 60
[IP_ADDRESS] Survival fo llow-up ............................................................................................ 60
8.2.9 COVID-19 Testing ............................................................................................ 60
8.3 Collection of adverse events.............................................................................. 60
8.3.1 Method of detecting AEs and SAEs ................................................................... 61
8.3.2 Time period and frequency for collecting AE and SAE information .................. 61
8.3.3 Follow-up of AE s and SAEs.............................................................................. 61
8.3.4 Adverse event data collection ............................................................................. 61
8.3.5 Caus ality collection ........................................................................................... 62
8.3.6 Adverse events based on signs and symptoms ................................................... 62
8.3.7 Adverse event s based on examinations and tests ................................................ 63
8.3.8 Hy‚Äôs law ........................................................................................................... [ADDRESS_277500] ...................................................................... 64CCI
Clinical Study Protocol ‚Äì 8.[ADDRESS_277501] OF TABLES
Table 1 Study objectives....................................................................................... 14
Table 2 Schedule of Activities - Screening............................................................ 19Table 3 Study objectives....................................................................................... 24
Table 4 Highly effective methods of contraception (<1% failure rate) ................... 39
Table 5 Restr icted med ications ............................................................................. 44
Table 6 Prohibited medications ............................................................................. 44
Table 7 Requirements for documentation of progression ....................................... 54
Table 8 Laboratory safety variables ...................................................................... 56
Table 9 AZD4635 dose modifications a nd discontinuation criteria for non-
hematologic toxicities (e xcept hyper tension)............................................ [ADDRESS_277502] OF APPENDICES
Appendix A Regulatory, ethical and study oversight considerations ............................. 83
Appendix B Adverse event definitions and additional safety information ..................... 89
Appendix C Handling of Human Biol ogical Samples................................................... 93CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 13 of 126Appendix E Actions required in cases of increases in liver biochemistry and
evaluation of Hy‚Äôs Law............................................................................. [ADDRESS_277503]
Version 1.1 (Response Evaluation Crite ria in Solid Tumors) in Soft
Tissue and PCWG3 (Prostate Cancer Working Group Criteria 3) in Bone
Lesions .................................................................................................. 108
Appendix I PCWG3 PSA Criteria............................................................................. 124
Appendix J Disallowed medications .......................................................................... 125
Appendix K Module 1: AZD4635 plus Durvalumab
Appendix L Module 2: AZD4635 plus Oleclumab
Appendix M Module 3: AZD4635 plus D urvalumab plus OleclumabCCI
CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 14 of 1261 PROTOCOL SUMMARY
1.1 Synopsis
Coordinating Principle Investigator
Columbia University Medical Ce nter/Herbert Irving Pavilion 
161 Fort Washington Avenue[LOCATION_001], NY [ZIP_CODE] [LOCATION_002]
Protocol Title:
An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients 
with Prostate Cancer
Rationale:
AZD4635 appears to have increased efficacy in combination with anti-programmed death 
ligand 1 in prostate cancer due to increased immune activation compared to single agent 
AZD4635. On study D8730C00001 in the Phase 1A dose e scalation portion, 12 patients with 
metastatic castrate-resistant prostate cancer were dosed with AZD4635, and prostate-specific 
antigen (PSA) responses were seen in 4 pati ents (2 in monotherapy and 2 in combination 
therapy). Three Response Evaluation Criteria in Solid Tumours responses were seen among these same patients with 1 complete response and 2 partial responses, all of which persisted 
for >6 months. Data from the ongoing Phase 1b portion of this study so far support the 
development of AZD4635 in combination in prostate cancer. Therefore, this open-label multi-center, modular Phase II study in p atients with prostate cancer consists of a number of
treatment cohorts, allowing evaluation of the efficacy, safety and tolerability of the study drug 
in multiple treatment arms.
Table 1 Study objectives
Primary Objective: Endpoint/Variable:
To evaluate efficacy of each combination therapy on 
objective response rate (ORR) for patients with 
measurable diseaseProportion of patients with measurable disease at 
baseline who have a confirmed ORR per Response 
Evaluation Criteria in Solid Tumours (RECIST 1.1)
To evaluate efficacy of each combination therapy on 
PSA response ratePSA confirmed response is defined as the proportion 
of participants with a reduction in the PSA level of
‚â•50% from baseline to the lo west post-ba seline PSA 
results, measured twice, at least 3 weeks apart by [CONTACT_230571] 3 criteria (PCWG3)[COMPANY_003]
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
Table 1 Study objectives
CONFIDENTIAL AND PROPRIETARY 15 of 126Secondary Objectives: Endpoint/Variable:
To evaluate the efficacy of each combination therapy 
on the proportion of patients alive andprogression-free at [ADDRESS_277504] 1.1 (soft 
tissue lesions) and PCWG3 (bone lesions)
To evaluate efficacy of each combination therapy on duration of response (DoR)Duration of Response (DoR) is defined as the time 
from the date of first documented response until date of documented progression or death in the absence of disease progression
To evaluate efficacy of each combination therapy on 
overall survival (OS).Overall survival is length of time from date of first 
dose until the date of death due to any cause.
To evaluate the pharmacokinetics (PK) of AZD4635 and its metabolites and other combination agent(s).Steady state trough
To evaluate the immunogenicity of mAB st udy 
drug(s) in combination with AZD4635.Patients with the presence or absence of anti-drug 
antibody (ADA)
Safety Objective: Endpoint/Variable:
To assess the safety and tolerability of each treatment regimen .Adverse events (AEs)/serious adverse events (SAEs) 
Physical exam and vital signs
Collection of clinical chemistry/hematology 
parameters
 
 
 
  
 
 
  
 CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
Table 1 Study objectives
CONFIDENTIAL AND PROPRIETARY 16 of 126 
 
  
 
 
  
 
 
 
  
 
 
 
 
  
Overall design:
This is an open-label Phase II modular study in patients with prostate cancer which will assess 
safety, efficacy, and tolerability of AZD4635 in co mbination with other therapeutic agents in 
different treatment arms. The details of the study design, including identification of the combination agents, will be described in appendices to the core protocol. Three appendices are included in Study D8731C00001 as specified below. The decision was made by [CONTACT_230572] 3 to recruitment after a comprehensive strategy review of the AZD4635 program and not due to new dose- limiting toxicities or concerning safety signals 
observed with AZD4635. Other combination agents may be identified and included in the study appendices under the auspi[INVESTIGATOR_230557] I ND or CTA amendments.
Appendix K Module 1: AZD4635 plus durvalumab 
Appendix L Module 2: AZD4635 plus oleclumabAppendix M Module 3: AZD4635 plus durvalumab plus oleclumab
All patients will be allocated into a module using the Interactive Web Response System 
(IWRS). Rando mization w ill occur when patients meet eligibility criteria for [ADDRESS_277505].CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 17 of 126Study Period:
Estimated date of first patient enrolled: Q3 [ADDRESS_277506] patient com pleted: Q2 2021
Administrative Structure:
Sarah Cannon Develop ment Innovations ha s been contracted by [CONTACT_230573] (CSP) version 7.
Parexel has been contracted to take over the management of the patients from Sarah Cannon 
Development Innovations from implementation of CSP version 7.
Study site(s) and number of patients planned:
There will be approximately [ADDRESS_277507] the study in multiple sites.
Treatments and treatment duration:
This protocol has a modular design, with the potential for future treatment arms to be added 
via protocol amendment. The core protocol ha s information about AZD4635 and refers to the 
following modules and study drugs. For specific information on each of the study drugs, please refer to the relevant module.
!Module 1: AZD4635 in combination with durvalumab
!Module 2: AZD4635 in combination with oleclumab
!Module 3: AZD4635 in combination with durvalumab and oleclumab
Additional modules and agents may be added as part of this multi-drug protocol as decisions 
on the most appropriate combinations to us e become available. A s ubstantial protocol 
amendment with relevant nonclinical and clinical data will be put in place before starting a new combination module.
Patients will continue to receive study tr eatment until one of the discontinuation criteria is met 
or withdrawal from study, whichever occurs first.
Statistical methods
The primary efficacy endpoint is  PSA decline from baseline ‚â•50% (PSA50) and overall 
response rate (ORR) per RECIST v1.1 for patients with measurable disease at baseline. In 
Modules 1, 2, and 3 (if conducted) there will be approximately [ADDRESS_277508] measurable disease at baseline 
in each m odule. Approx imately 30 patients with and without measurable disease at baseline
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 19 of 1261.3 Schedule of Activities (SoA) - Screening
The Schedule of Activities (SoA) for the pre-screening and screening visits is shown in Table
2below. For the SoA to be performed during the on-treatment period, please refer to the 
relevant module.
Table 2 Schedule of Activities - Screening
Screening Details in Section
Informed consentaX 5.1
Inclusion/exclusion X 5
Medical history and demographicsb
X4.1.2
Physical examinationbX 8.2.2
ECOG performance statusbX 8.2.3
Vital signsbX 8.2.4
Height and weightbX 8.2.4
12-lead ECG (triplicate)bX 8.2.5
ECHO/ MUGA scanbX 8.2.6
HematologybX 8.2.1
Clinical chemistry (including LDH, thyroid panel, and 
CRP)b X8.2.1
Testosterone samplebX 8.2.1
Prostate-specif ic antigen (PSA)d X8.1.[ADDRESS_277509] (PT/INR/aPTT)bX 8.2.1
Hepatitis A, B, C; HIV-1bX 8.2.1
Archival tumor sampleeX 8.8.2
Concomitant med ication X 6.6
Adverse event (AE) evaluation X 8.3
Fresh tumor biopsyfX [IP_ADDRESS]
Tumor assessments CT/MRI/PET and Bone scanscX 8.1.[ADDRESS_277510] be obtained ‚â§28 days prior to the initiation of t reatment and before any study-
specific procedures are performed.CCI
CCI
CCI
CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 20 of 126bAssessments should be done ‚â§14 days prior to initiation of treatment. If these assessments are performed 
within 72 hours of initiation of treatment, they do not need to be repeated, with the exception of the ECOG 
performance status, abbreviated physical examination, vital si gns (including respi[INVESTIGATOR_230558]) weight, 
and triplicate ECGs required prior to first study dose. The testosterone sample may be taken within 28 days 
of screening. Urinalysis should be repeated on Day 1 of every cycle, at the end-of-treatment (EOT) visit, 
and if clinically indicated. The Hepatitis A laboratory test should only be performed if the patient is 
considered symptomatic per the Investigator.
cBaseline tumor assessments should be performed no more than [ADDRESS_277511] measurable PSA ‚â•1.0 ng/mL as the minimum starting level for trial entry if the 
confirmed rise is the only indication of progression (excluding pure small cell carcinoma). It is recommended to estimate a pre-treatment PSA doubling time (PSADT) if at least 3 values are available ‚â•4 
weeks apart. Treatment or enrollment onto a trial should not be delayed to estimate PSADT.
eAll patients will be required to provide a sample of their archival tumor, if available (tissue from the primary lesion or a metastatic site is acceptable). The archived tumor samples will preferably be in the form of a formalin fixed paraffin embedded (FFPE) block. If archival tumor tissue is not available, then tissue from a fresh tumor biopsy is required.
fAll patients will be required to have a site of disease that is safely accessible for biopsy (paired) upon 
enrollment unless there are sufficient paired samples for the analysis as determined by [CONTACT_1034]. The 
initial predose biopsy should be taken within 30 days of screening (at least [ADDRESS_277512] administration of AZD4635) and 2 weeks after the initiation of AZD4635 therapy. A 5-day window is permitted to facilitate on-treatment biopsy collection (Days [ADDRESS_277513] dose of AZD4635). The time and site of the biopsy must be clearly documented. Instructions for processing of biopsies are in the Laboratory Manual.
gCCI
Clinical Study Protocol ‚Äì 8.[ADDRESS_277514] frequently diagnosed cancer in men and was estimated to
be responsible for over 300,000 deaths worldwide in 2018 ( Bray et al. 2018) . For patients 
who require systemic therapy, the mainstay of  treatment is hormonal therapy but patients
often develop resistance to this therapy (castrate-resistant prostate cancer). Treatment for both metastatic and non-metastatic prostate cancer is rapi[INVESTIGATOR_92311]. Since the development of a docetaxel regimen for the treatment of metastatic castration-resistant prostate cancer(mCRPC) in 2004 (Tannock et al. 2014) , the outcomes of this condition have improved 
dramatically. However, many of the tr eatments for prostate cancer, including docetaxel and 
cabazitaxel for mCRPC, may not be suitable for all patients and some patients are refractoryto these treatments, thus there remains a need for additional therapi[INVESTIGATOR_28060].
Current standard of care (SOC) therapi[INVESTIGATOR_230559], and abiraterone 
plus prednisone. Enzalutamide, a targeted androgen-receptor inhibitor that blocks binding of androgen to the androgen-receptor, translocation to the nucleus, and DNA binding (Tran et al.
2009) , was approved for the first-line treatment of patients with mCRPC and metastatic 
castration-sensitive prostate cancer (mCSPC). Abiraterone, a selective inhibitor of 17 Œ±-
hydroxylase/C17,20-lyase (CYP17) wa s also approved in combination with prednisone for the 
treatment of mCRPC in th e first-line setting (Ryan et al. 2013a, Ryan et al. 2013b) and for 
metastatic high-risk castration-sensitive prostate cancer.
2.[ADDRESS_277515] of care (SOC) treatments for mCRPC, better treatments are needed for patients after the SOC options have been exhausted.
AZD4635 is being developed as monotherapy and in combination with other agents to 
augment the anti-tumor immune response. Ongoing studies D8730C00001 and D6070C00004 include the combination of AZD4635 with durvalumab (anti-PDL1 monoclonal antibody) as well as in combination with oleclumab (CD73 mAb), respectively. On study D8730C00001in the Phase 1A dose escalation portion, 12 patien ts with metastatic CRPC were dosed with 
AZD4635, and PSA responses were seen in 4 patients (2 in monotherapy and 2 in
combination therapy). Three RECIST responses were seen among these same patients with
1 CR and 2 PRs, all of which persisted for >6 months. Data for the ongoing Phase 1b portion 
of the study so far support the development of AZD4635 in combination in prostate cancer. Therefore, this open-label multi-center, modul ar Phase II study in patients with prostate 
cancer consists of a number of treatment cohorts, allowing evaluation of the efficacy, safety and tolerability of the study drug in multiple treatment arms.
Study rationale for each module is provided in the modular-specific appendix.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277516] been 
shown to induce durable responses in several cancers (Larkin et al. 2015, Robert et al. 2015,
Brahmer et al. 2015, McDermott et al. 2015, Le et al. 2015, Antonia et al. 2017) . However, 
immune suppression in the tumor microenvironment (TME) can lead to immune evasion, decrease effectiveness of T cells, and impact primary resistance or acquired resistance to 
immunotherapy. Extracellular adenosine signaling through adenosine 2a receptor (A
2AR) is 
one such mediator of immune suppression which leads to decreases in antigen presentation and T-cell activation, as well as an increase i n suppressive cells . Modulation of the TME with 
drugs that decrease adenosine or inhibit the A
2AR may reverse these effects and enable the 
host to mount an effective anti-tumor immune response, even in tumor types that are not 
typi[INVESTIGATOR_230560].
AZD4635 is a potent, highly selective inhibitor of A 2AR. In preclinical mechanistic, efficacy 
and pharmacodynamic (PDx) studies, AZD4635 demonstrates activity consistent with 
enhancement of anti-tumor immunity.  
 
 
 
 
 
AZD4635 appears to have increased efficacy in combination with anti-programmed death 
ligand 1 in prostate cancer due to increased immune activation compared to single agent AZD4635. As of October 4, 2018, in the ongoing study D8730C000 01, prostate-s pecific 
antigen (PSA) responses were seen in 4 of 10 patients with advanced prostate cancer (2 patients in AZD4635 monotherapy [Phase 1a], and 2 patients receiving AZD4635 in 
combination with durvalumab [Phase 1a]). In Phase 1a, 8 patients had disease measurable by 
[CONTACT_118506] 1.1 (RECIST v1.1) and were observed to have 2 partial responses (1 in a monotherapy cohort, 1 in AZD4635 + durvalumab combination cohorts) and 1 complete response (in an AZD4635 + durvalumab combination cohort). All of these responses persisted for >6 months (11-16 months). Data from this ongoing study appear to suggest a higher response rate in prostate cancer following combination therapy with AZD4635 + durvalumab over AZD4635 monothera py. Although 
the combination of anti-CD73 (oleclumab) with AZD4635 has not been studied specifically inCCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 23 of 126prostate cancer, there is an ongoing study of oleclumab with AZD4635 in refractory epi[INVESTIGATOR_33927] (EGFR)-mutant non-small cell lung cancer (NSCLC) post-tyrosine kinase inhibitor (TKI) progression. This co mbination provides inhibition of the adenosine 
axis by [CONTACT_230574] A
2AR blockade and is hypothesized to 
increase the response seen with either single agent alone by [CONTACT_230575]-mediated immunosuppression. This hypothesis is also applicable to patients with prostate cancer.
A detailed description of the chemistry, pharmacology, efficacy, and safety of AZD4635 is 
provided in the Investigator‚Äôs Brochure (IB).
2.3 Benefit/risk assessment
AZD4635 is a novel A 2AR antagonist agent that acts against cancer by [CONTACT_230576]-mediated A 2AR signaling in tumor infiltr ating cells. AZD4635 blockade is
hypothesized to modulate the TME so that an active anti-tumor immune response will be more 
effective. Therefore, AZD4635 may have the potential to provide benefit in terms of increased efficacy in patients with a variety of advanced solid malignancies and for patients who are refractory to SOC treatments.
As of December 2019, approximately [ADDRESS_277517] 2016 
and 20 June 2019 (date of data cut-off) in the ongoing study D8730C00001, 94 mCRPC patients were treated with AZD4635 (125 mg BID, 75 mg QD, or 100 mg QD oral nanosuspension Q3W monotherapy [n=49]) or in combination (75 or 100 mg QD) with durvalumab 1.5g IV Q4W (n=45).
As of December 17, 2018, 17 healthy volunteer s had received AZD4635 nanosuspension or 
AZD4635 capsule formulation in study D8730C00002. As of October 05, 2018 in study 
D6070C00004, 8 patients had received AZD4635 at 2 dose levels in combination with oleclumab.
Based on the available safety data, nausea and vomiting are identified risks for AZD4635 
when it is used as monotherapy or given in combination with durvalumab or oleclumab. In 
study D8730C00001, 2 serious adverse events (SAE s) were reported for AZD4635 (at various 
dose levels) in combination with durvalumab which were considered related to study treatment by [CONTACT_32366]: d iabetes mellitus type 1 (Grade 4) and hypertension (Grade 3). 
In Study D6070C00004, 1 SAE of pulmonary embolism (Grade 3) was considered related to 
the combination of AZD4635 and oleclumab by [CONTACT_737]. Although, thrombosis is considered to be an important potential risk for oleclumab based on known mechanism of action, it is not  considered to be a risk for AZD4635.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277518] common treatment-emergent AEs (TEAEs) seen in patients treated with AZD4635 
as monotherapy or in combination across all studies were mainly nausea, vomiting and 
fatigue. These AEs were mostly Grade 1 or 2 and were clinically manageable. One patient in study D8730C00001, in the Phase 1a dose escalation cohort of the combination
(75 mg AZD4635 + 1500 mg durvalumab), experienced Grade 2 dose- limiting toxicities 
(DLTs) of nausea and fatigue which required dose reduction of AZD4635 to 50 mg.
In study D8730C00001, 70 patients were evaluable for tumor response (monotherapy=33, 
combination=37). RECIST v1.1 responses were confirmed in 8 participants: 
(monotherapy=ORR 6.1% [2 PRs]) and (combination=16.2% [2CRs, 4PRs]). The median PFS for the monotherapy cohort was 13.6 weeks ( 95% confidence interval [CI], 7.1-15.3) and
14.9 weeks (95% CI, 13.3-29.3) for the combination cohort. PSA response (defined as ‚â•50% 
decrease from baseline) was observed in monotherapy=6.4% (3/47 patients; 95% CI, 1.3-
17.5%) and combination=20% (9/45 participants; 95% CI, 9.6 34.6%).
More detailed information a bout the known and expected benefits and risks and reasonably 
expected AEs of each study drug may be fo und in their drug-specific IBs and the relevant 
modules. Appendix A in Modules 1 and 2 describes risk considerations for COVID-19.
3 OBJECTIVES AND ENDPOINTS
Table 3 Study objectives
Primary Objective: Endpoint/Variable:
To evaluate efficacy of each combination therapy on 
objective response rate (ORR) for patients with 
measurable diseaseProportion of patients with measurable disease at 
baseline who have a confirmed ORR per Response 
Evaluation Criteria in Solid Tumours (RECIST 1.1)
To evaluate efficacy of each combination therapy on 
PSA response ratePSA confirmed response is defined as the proportion 
of participants with a reduction in the PSA level of‚â•50% from baseline to the lowest post-baseline PSA 
results, measured twice, at least 3 weeks apart by [CONTACT_230577] 3 criteria (PCWG3)
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
Table 3 Study objectives
CONFIDENTIAL AND PROPRIETARY 25 of 126Secondary Objectives: Endpoint/Variable:
To evaluate the efficacy of each combination therapy 
on the proportion of patients alive andprogression-free at [ADDRESS_277519] 1.1 (soft 
tissue lesions) and PCWG3 (bone lesions)
To evaluate efficacy of each combination therapy on 
duration of response (DoR)Duration of Response (DoR) is defined as the time 
from the date of first documented response until date of documented progression or death in the absence of disease progression
To evaluate efficacy of each combination therapy on 
overall survival (OS).Overall survival is length of time from date of first
dose until the date of death due to any cause.
To evaluate the pharmacokinetics (PK) of AZD4635 
and its metabolites and other combination agent(s).Steady state trough
To evaluate the immunoge nicity of mAB study 
drug(s) in combination with AZD4635.Patients with the presence or absence of anti-drug 
antibody (ADA)
Safety Objective: Endpoint/Variable:
To assess the safety and tolerability of each treatment 
regimen .AEs/SAEs
Physical exam and vital signsCollection of clinical chemistry/hematology 
parameters
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
Table 3 Study objectives
CONFIDENTIAL AND PROPRIETARY 26 of 126 
 
 
 
  
 
  
 
 
 
 
  
 
 
  
 
 
  
 
 
 
  
 
 
 
  
4 STUDY DESIGN
4.1 Overall design
This is an open-label Phase II modular study in patients with prostate cancer to assess safety, 
efficacy, and tolerability of AZD4635 in combination with other therapeutic agents in different treatment modules. Patients will be randomized for inclusion in the initial 3 modulesCCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 28 of 126aThe decision was made by [CONTACT_230578] 3 to recruitment after a comprehensive strategy 
review of the AZD4635 program and not due to new dose-limiting toxicities or concerning safety signals 
observed with AZD4635.
Study drug-specific information including doses and justifications, toxicity management, dose 
modifications and concomitant medications for AZD4635 can be found in the core protocol. Study drug-specific information including doses and justifications, toxicity management, dose 
modifications and concomitant medications for additional study agents can be found in the 
relevant module.
[IP_ADDRESS] List of modules
The following modules for the study are included with this protocol. The structure of the 
protocol allows for further modules to be added t o the core study via protocol amendment as 
required.
!Module 1: AZD4635 in combination with durvalumab (Appendix K)
!Module 2: AZD4635 in combination with oleclumab (Appendix L)
!Module 3: AZD4635 in combination with durvalumab and oleclumab (Appendix M)
As stated above, the modules contain study drug-specific information. Specific rationales for 
these cohorts are provided in the modules.
4.1.2 Clinical screening procedures
Each potential patient will provide informed consent ‚â§[ADDRESS_277520] dose of study drug.
The following screening procedures, which are common to each of the modules, should be 
performed (please also refer to  Table 2) :
!Demographic data and other characteristics will be recorded and will include date of birth 
or age, gender, and race and/or ethnicity per local regulations.
!A standard medical, medication and surgical history, including prior cancer tr eatments, 
response, and duration of prior therapy, will be obtained.
!The following clinical assessments will be required:
oPhysical examination and ECOG performance s tatus ev aluation
oVital signs + weight and height
oECG
oECHO/MUGA scan
oBlood samples collection including testosterone and PSA
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 29 of 126oUrine sample collection
oTumor assessments: CT/MRI/PET and Bone scans per RECIST v.1.1 and 
PCWG3
!All patients will be required t o provide an archival tumor b lock (if available) or a new 
fresh tumor biopsy if an archival sample is not available (this biopsy sample is not to 
replace the fresh paired biopsy collection described below).
!A fresh biopsy will be required within [ADDRESS_277521] be made clear to each patient at the time 
of initial approach by [CONTACT_737].
!At screening, consenting patients are a ssessed to ensure that they meet the core and 
module-specific eligibility criteria for one or more modules.
!All eligible patients will then be assigned into a module via IWRS system. 
Randomization will occur when patients meet eligibility criteria for [ADDRESS_277522].
!All patients, after being assigned into a module, will need to consent for a 
module-specific ICF prior to the 1
stdose on study.
Samples for laboratory tests for the assessment of safety will be sent to a local laboratory and 
assessed locally. All other samples such as those for the assessment of molecular aberrations 
 will be assessed centrally. The tumor sample(s) taken as part of 
the screening procedures will be sent to a central laboratory(ies) for analysis of molecular 
alterations using tests verified and validated in line with local regulations e.g., Clinical Laboratory Improvement Amendmen ts/College of Amer ican Pathologists (CLIA/CAP) for US 
laboratories, Good Clinical Practice (GCP), and local accreditation for other territories.
4.1.3 COVID-19 testing (if applicable)
During the study, tests for active c oronavirus disease of 2019 (COVID-19) infection may be 
conducted, if required, and in accordance with local guidance.
If a patient is symptomatic for active COVID-[ADDRESS_277523]. Dosing may continue while results are awaited, per the Investigator‚Äôs discretion and local guidelines, and the Medical Monitor/Study Physician should be consulted. If a patient tests positive for COVID-19, the study drugs may be temporarily interrupted and later resumed, pe r the Investigator‚Äôs discretion and local 
guidelines, and this s hould be discussed with the Medical Monitor/Study Physician. WhereCCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 30 of 126applicable, home, or remote visits may be conducted for study assessments and study drug 
administration (refer to Appendix A in Modules 1 and 2).
4.[ADDRESS_277524] been exhausted. AZD4635 is being developed as monotherapy and as an immuno-oncology agent in combination with durvalumab (MEDI4736, PD-L1 monoclonal antibody [mAb]) and in combination with oleclumab (MEDI9447, CD73 mAb), exploiting compleme ntary immune-r elated mec hanisms to broaden 
and deepen clinical responses in prostate cancer.
AZD4635 had been studied clinically in 3 other investigational trials prior to initiation of this 
protocol:
!D8730C00001 ([STUDY_ID_REMOVED]): This first-time-in-human (FTIH) study of AZD4635 is a 
Phase 1 study that dosed AZD4635 at the maximum-tolerated dose (MTD) of 100 mg 
orally (PO) daily (QD) both as monotherapy and in combination with durvalumab in 
patients with advanced solid tumors.
!D8730C00002 ([STUDY_ID_REMOVED]): A bioavailability study in healthy volunteers was 
undertaken in order to facilitate a change in formulation and compare the performance of 
a capsule formulation to the existing nanosuspension to assess the 2 formulation variants.
!D6070C00004 ([STUDY_ID_REMOVED]): AZ D4635 is also being studied at 75 and 50 mg PO QD 
in combination with oleclumab (MEDI9447) 1500 mg intravenously (IV) every 2 weeks (Q2W) in patients with refractory EGFRm lung cancer. Patients developed significant 
nausea and vomiting at the starting dose of AZD4635 75 mg QD + oleclumab 1500 mg. 
However, dose reduction to 50 mg AZD4635 nanosuspension daily in combination with 
oleclumab 1500 mg IV is still under evaluation.
Please see the AZD4635 IB for more information.
4.3 Justification for AZD4635 dose
 
 
 
 
 CCI
CCI
Clinical Study Protocol ‚Äì 8.[ADDRESS_277525] assessment was conducted as part of the relative bioavailability 
study (Study D8730C00002) in h ealthy volunteers to assess the impact of a high-fat meal on a 
single dose of capsule formulation of AZD4635. Interim PK data from [ADDRESS_277526] 
co-administration of AZD4635 capsule with a high-fat meal decreased AZD4635 geometric 
mean AUC0-48 by 15%, decreased geometric mean C maxby [CONTACT_3450] 50%, and delayed
tmaxby 2.[ADDRESS_277527] patient undergoing 
the study. There will be a primary analysis data cut-off (DCO) for th e study (Modul es 1 and 
2) at approximately [ADDRESS_277528] (IP) or
90 days after the final patient discontinues IP if this is earlier. The clinical study database will 
be closed to new data after the DCO (16 June 2022) for the primary analysis.
The study may be terminated at individual centers if the study procedures are not being 
performed according to Good Clinical Practice (GCP) or if the site is unable to recruit sufficient numbers of patients into the study.CCI
CCI
Clinical Study Protocol ‚Äì 8.[ADDRESS_277529] meet all of the inclusion cri teria and none of the exclusion criteria for this 
study in order to be assigned/randomized to  a study module. Under no circumstances can 
there be exceptions to this rule. Patients w ho do not meet the entry requirements are screen 
failures (refer to Section  5.4).
Where there are differences in stringency or cut-off values between the core protocol and 
specific module, the specific module takes precedence. For example, if hematological or medication parameters are stricter in the modul e than in the core protocol, the Investigator 
should adhere to the module criteria.
In this protocol, ‚Äúenrolled‚Äù patients are defi ned as those who sign informed consent forms 
(ICFs). ‚ÄúRandomized‚Äù patients are defined as thos e who undergo randomization and receive a 
randomization number or are assigned to a m odule.
For procedures for withdrawal of incorrectly enrolled patients see Section 7.3.
5.1 Inclusion criteria
The inclusion criteria that are applicable to all patients in the study are described in this 
section. Please also refer to the relevant modul e protocol for specific criteria applicable to 
each m odule.
Inclusion Criteria for all patients in all modules
Patients are eligible to be included in the study only if all of the following inclusion criteria 
are met and none of the exclusion criteria apply:
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 33 of 126Informed consent
1 Ability to provide signed infor med consent, which includes compliance with the 
requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
2 Provision of signed and dated, wri tten i nformed consent form prior to any mandatory 
study-specific procedures, sampling, and analyses.
 
 
 
The ICF process is described in Appendix  A3 .  
Age
3 P a t i e n tm u s tb e ‚â•[ADDRESS_277530] of care therapy(ies).
[ADDRESS_277531] a site of disease that is safely accessible for biopsy 
(paired) upon enrollment unless there are sufficient paired samples for the analysis as determined by [CONTACT_1034]. Accessible lesions are defined as those which are biopsiable 
(at screening) and amenable to repeat biopsy (after 2 weeks of AZD4635 therapy), unless clinically contraindicated.
The provision of paired biopsies will be closely monitored to ensure the desired number 
of biopsiable patients are enrolled and Investigators are aware of this requirement at all times.
[ADDRESS_277532]:
!At least 1 documented lesion on either a bone scan or a computed tomography (CT)/ 
magnetic resonance imaging (MRI) scan that can be followed for response and is suitable 
for repeated measurement (see  Appendix G) .
OrCCI
CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 34 of 126!Patients with non-measurable disease must have measurable PSA ‚â•1.0 ng/mL as the 
minimum starting level for trial entry if the confirmed rise is the only indication of 
progression (excluding small cell carcinoma).
9 Eastern Cooperative Oncology Group (ECOG) performance status of [ADDRESS_277533] 12 weeks
Sex
12 Male
Weight
13 Body weight ‚â•35 kg at screening
Reproduction
14 Willingness to adhere to the study treatment-specific contraception requirements: Male 
patients must be surgically sterile or using an acceptable method of contraception(defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time they sign ICF) and for [ADDRESS_277534] not enter the study if any of the following exclusion criteria apply:
Medical conditions
1 History or presence of another primary invasive malignancy except for:
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 35 of 126‚àÄMalignancy treated wi th curative intent and with no known active disease ‚â•[ADDRESS_277535] dose of study drug and of low potential risk for recurrence.
‚àÄAdequately treated non- melanoma skin cancer or lentigo maligna without evidence of 
disease.
‚àÄAdequately treated carcinoma in situ without evidence of disease.
‚àÄLocalized non-invasive primary carcinoma under surveillance.
[ADDRESS_277536] 21 days previously and 
there is no evidence of CNS disease progression or mild neurologic symptoms
4 With the exception of alopecia, lymphopenia, and hypothyroidism, any unresolved 
toxicities from prior therapy greater than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) Grade 1 at the time of starting study treatment.
5 Patients with prior ‚â•Grade 3, serious, or life-threatening immune-mediated reactions 
following prior anti-PD-1, anti-PD-L1, or other immuno-oncology therapi[INVESTIGATOR_014].
[ADDRESS_277537] normotensive or well controlled BP (<150/90), with or without current 
antihypertensive tr eatment. If there is a diagnosis or history of hypertension, patient must 
have adequately controlled BP on antihyper tensive medications, as demonstrated by [ADDRESS_277538] BP readings twice-daily for a minimum of 3 weeks.
8 As judged by [CONTACT_230579], any evidence of severe or uncontrolled 
systemic diseases, including active bleeding diatheses, or active infection including tuberculosis (clinical evaluation that include s clinical history, physical examination and 
radiographic findings, and tuberculosis testing in line with local practice), hepatitis B 
virus (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 anti bodies). Active hepatitis A as judged by 
[CONTACT_737]. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C virus (HCV) an tibody are eligible only if polymerase chain 
reaction is negative for HCV RNA. Screening for chronic conditions is not required.
9 Active or prior documented autoimmune or inflammatory disorders (including 
inflammatory bowel disease [e .g., colitis, Crohn' s disease], diverticulitis, celiac disease, 
systemic lupus erythematous, Weg ener's syndrome, myasthenia gravis, Grave's disease,
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 36 of 126rheumatoid arthriti s, hypophysitis, uveitis, autoimmune pneumonitis, autoimmune 
nephritis or nephropathy, etc.) within the past 3 years prior to the start of tr eatment. The 
following are exceptions to this criterion:
‚àÄVitiligo or alopecia
‚àÄHypothyroidism (e.g., following Hashimoto's disease) stable on hormone 
replacement
‚àÄPsoriasis or eczema not requiring sys temic therapy for di sease control
‚àÄCeliac disease controlled by [CONTACT_33119].
Prior/concomitant therapy
10Prior therapy with AZD4635 or any other A 2AR antagonist.
11 Ongoing corticosteroid use, at doses above physiologic rep lacement therapy. The 
following are exceptions to this criterion:
‚àÄUse of intranasal, inhaled, topi[INVESTIGATOR_11930], local steroid injections (e.g. 
intra-articular injections)
‚àÄSteroids as pre-medication for hypersensitivity r eactions (e.g. CT scan 
pre-medication) are permitted
‚àÄSystemic corticosteroids at physiologic doses below 10 mg/day of prednisone or 
equivalent.
[ADDRESS_277539] be observed:
‚àÄAnti-cancer therapy: ‚â•21 days or 5 half-lives (whichever is shorter) of the first dose 
of study drug. At least [ADDRESS_277540] dose of study drug. Exception: Androgen-deprivation therapy is 
required to maintain castrate levels of testosterone (<50 ng/dL).
‚àÄConcurrent use of hormones for non-cancer-related conditions (e.g., insulin for 
diabetes and hormone replacement therapy) is acceptable.
13 Major surgery (as defined by [CONTACT_1689], excluding placement of vascular 
access) within [ADDRESS_277541] dose of study treatment.
14 Minor surgical procedures (as defined by [CONTACT_1689]) within [ADDRESS_277542] cancer 
resistance protein (BCRP) or organic anion transporter polypeptide 1 ( OATP1B1), OATP1B3, OAT1, organic cation transporter 1 (OCT1), OCT2, multi-drug and toxin 
extrusion protein 1 (MATE1) and P-glycoprotein (P-gp) substrates or potent or moderate 
inhibitors/inducers of CYP1A2, which cannot be discontinued [ADDRESS_277543] dose of AZD4635.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277544] that would increase risk of seizure 
(e.g., theophylline, aminophylline).
[ADDRESS_277545] dose of study drug.
20 Herbal preparations/medications are not allowed throughout the study. These herbal 
medications include, but are not limited to: St. John‚Äôs wort, kava, ephedra (ma huang), ginkgo biloba, dehy droepi[INVESTIGATOR_2119], yoh imbe, saw palmetto, and ginseng. Patients 
should stop using these herbal medications [ADDRESS_277546] dose of study tr eatment.
22 Enrollment into another therapeutic clinical trial. Exception: Patients are allowed to 
participate in investigational imaging or non-interventional studies.
23 History of hypersensitivity to AZD 4635 or drugs with a similar chemical structure or 
class to AZD4635.
Diagnostic assessments
24 Any of the following cardiac criteria:
‚àÄMean resting corr ected QT interval (QTcF) >470 msec obtained from 3 ECGs
‚àÄAny clinically important abnormalities in rhythm, conduction, or morphology of 
resting ECGs, e.g., complete left bundle branch block, third degree heart block
‚àÄAny concomitant medication with known risk of QT interval prolongation. Patients 
receiving a medication(s) known to prolong the QT  interval may be discussed with 
the Medical Monitor or Sponsor for study approval.
‚àÄEjection fraction <55% or the lower limit of normal of the institutional standard.
25 Inadequate bone marrow reserve or organ function as demonstr ated by [CONTACT_230580]:
‚àÄAbsolute neutrophil count <1.5 x 10
9/L
‚àÄPlatelet c ount <100 x 109/L
‚àÄHemoglobin <9.0 g/dL
‚àÄAlanine aminotransferase (ALT) >2.5 times the upper limit of normal (ULN) if no 
demonstrable liver metastases or >[ADDRESS_277547] in the presence of liver metastases
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 38 of 126‚àÄAspartate aminotransferase (AST) >2.[ADDRESS_277548] if no demonstrable liver 
metastases or >[ADDRESS_277549] in the presence of liver metastases
‚àÄTotal bilirubin (TBL) >1.[ADDRESS_277550]
‚àÄCreatinine >1.[ADDRESS_277551] concurrent with creatinine clearance <50 mL/min 
(measured or calculated by [CONTACT_230581]); confirmation of creatinine 
clearance is only required when creatinine is >1.[ADDRESS_277552].
Other exclusions
26 Involvement in the planning and/or conduct of the study (applies to [COMPANY_008] staff and 
its representatives and/or staff at the study site).
[ADDRESS_277553] one dose of study drug in the present study.
 
5.3 Lifestyle restrictions
Please refer to the relevant modules. Where restrictions are more stringent in the module 
rather than the core protocol, the Investigator should adhere to the module criteria.
5.3.1 Meals and dietary restrictions
Whenever possible, all doses of AZD4635 s hould be taken at appro ximately the same times 
each day with or without food.
5.3.2 Reproduction
The following restrictions apply while the pat ient is receiving AZD 4635 study treatment and 
for the specified times before and after:
!Male patients should be asked to avoid unprotected sex with women of childbearing 
potential during the study and for a washout period of 3 months after discontinuing study treatment. Patients should refrain from donating sperm from the start of dosing until 24 
weeks after discontinuing study treatment. If male patients wish to father children theyCCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 39 of 126should be advised to arrange for freezing of sperm samples prior to the start of study 
treatment.
!Female partners (of childbearing potential) of male patients must also use a highly 
effective method of contraception throughout this period.
Highly effective methods of contraception, defined as those that result in a low failure rate 
(i.e., less than 1% per year) when used consistently and correctly, are described in  Table 4.
Note that some contraception methods are not considered highly effective (e.g., male or 
female condom with or without spermicide; female cap, diaphragm, or sponge with or without spermicide; non-copper containing intrauter ine device; progestoge n-only oral hormonal 
contraceptive pi[INVESTIGATOR_230561] [excluding 
Cerazette/desogestrel which is considered highly effective]; and triphasic combined oral contraceptive pi[INVESTIGATOR_3353]).
Table 4 Highly effective methods of contraception (<1% failure rate)
Barrier/intrauterine methods Hormonal methods
! Copper T intrauterine device
! Levonorgestrel-releasing intrauterine 
system (e.g., Mirena¬Æ)a
aThis is also considered a hormonal method! Implants: Etonogestrel-releasing implants 
(eg, Implanon¬Æ or Norplant¬Æ)
! Intravaginal Devices: 
Ethinylestradiol/etonogestrel-releasing intravaginal devices (eg, NuvaRing¬Æ)
! Injection: Medroxyprogesterone injection 
(eg, Depo-Provera¬Æ)
! Combined Pi[INVESTIGATOR_4382]: Normal and low dose combined oral contraceptive pi[INVESTIGATOR_4382]
! Patch: Norelgestromin/ethinylestradiol-
releasing transdermal system (eg, Ortho Evra¬Æ)
! Minipi[INVESTIGATOR_4382]: Progesterone based oral contraceptive pi[INVESTIGATOR_72908]: Cerazette¬Æ is currently the only highly effective progesterone based pi[INVESTIGATOR_230562]-sp ecific guidance for reproduction information on other st udy 
treatment.
5.[ADDRESS_277554] udy treatment or do not meet the criteria for 
participation in the study.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 40 of 126A minimal set of screen failure information is required to ensure transparent reporting of 
screen failure patients to meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements and to respond to que ries from Regulatory Authorities. Minimal 
information includes demography, screen failure details, eligibility criteria, and any SAE.
Patients defined as screen failures may be rescreened unde r certain circumstances. 
Consideration will be given, for example, to the following:
!Patients with out-of-range laboratory values will be allowed to repeat the relevant 
laboratory safety assessments within the screening period, unless the laboratory values are 
reflective of an established medical condition and are unlikely to improve during the 
screening period.
!Patients for whom Screening procedures a re not completed within the 28-day window.
!Patients taking a prohibited medication can be considered for the study after the 
appropriate washout period. This is only applicable in instances where the withdrawal of 
the medication is clinically appropriate and unlikely to adversely affect the condition for 
which the medication has been prescribed.
Other conditions may be discussed with the Medical Monitor.
Patients may not be rescreened if they had previously concluded screening and had already 
been allocated to a module. However, rescreening should be documented so that its effect on study results, if any, can be assessed. All rescreened requests need to be discussed by [CONTACT_1689].
6 STUDY TREATMENTS
Please refer to each modular-specific appendix for details of the investig ational produ cts (IPs) 
that are applicable to each module of the study. Details for AZD4635 capsule (which will be used in each module) are described in this section.
6.1 Treatments administered
6.1.1 Investigational products
AZD4635
Study treatment name: [CONTACT_99213]4635
Dosage formulation: Capsule
Route of administration Oral
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 41 of 126AZD4635
Dosing instructions: Whenever possible, all doses of AZD4635 should be taken at 
approximately the same times each day with or without food. 
Should a patient miss a scheduled dose, the patient will be
allowed to take the dose up to a maximum of 4 hours after the
scheduled dose time. If gr eater than 4 hours after the s cheduled 
dose time, the missed dose should not be taken, and the patient should take the allotted dose at the next scheduled time. If a 
patient needs to take the dose earlier for any reason, the patient 
can take the dose up to 4 hours earlier than the scheduled dose 
time. The patient should make every reasonable effort to take 
the study drugs on time.
Packaging and labeling Study treatment will be provided in high-density polyethylene 
(HDPE) bottles induction-sealed with desiccant .Each bottle 
will be labeled in accordance w ith Good Manuf acturing Practice 
(GMP) Annex 13 and per country regulatory requirements.
6.2 Preparation/handling/storage/accountability
AZD4635 capsule s hould be stored in the pa ck provided according to the storage conditions 
on the label.
The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transi t for all study treatment r eceived and any discrepa ncies are reported 
and resolved before use of the study treatment.
Only patients enrolled in the study may receiv e study treatment and only authorized site staff 
may supply or administer study treatment. All stud y treatments must be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with the 
labeled storage conditions with access limited to the Investigator and authorized site staff.
The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance (i.e., 
receipt, reconciliation, and final disposition records).
Further guidance and information for the final disposition of unused study tr eatment are 
provided in the module-sp ecific pharmacy manual.
6.3 Measures to minimize bias
This is an open-label study. Recruitment to each module will be centrally assigned using 
IWRS. Before the study is initiated, the log-in information and directions for the IWRS will be provided to each site. Potential bias will be reduced by [CONTACT_230582], whenever 2 
or more modules are c urrently recruiting as follows:
Clinical Study Protocol ‚Äì 8.[ADDRESS_277555] .
If a patient withdraws from the study, then his enrollment/randomization code cannot be 
reused. Withdrawn patients will not be replaced; however, any patient that is withdrawn and 
is not evaluable may be replaced to ensure a minimum number of evaluable patients.
6.4 Treatment compliance
Treatment compliance will be assured by [CONTACT_230583].
It is the Investigator‚Äôs/institution‚Äôs responsib ility to establish a system for handling study 
treatments, including investigational products, to ensure that:
!Deliveries of such products from [COMPANY_008] or its representative are correctly received 
by a responsible person.
!Such deliveries are recorded.
!Study treatments are handled and stored safely and properly as stated on the label.
!Study treatments are only dispensed to study patients in accordance with the protocol.
At the end of the study, it must be possible to reconcile delivery records with records of usage 
and destroyed/returned stock.
Any change from the dosing schedule, dose interruptions, dose reductions, and dose 
discontinuations should be recorded in the electronic case report form (eCRF).
Patients should return all used and unused AZD4635 and empty containers. The Investigator 
or pharmacy must retain records of all study drugs administered.
The study personnel at the investigational site will account for all drugs dispensed and for 
appropriate destruction. Certificates of delivery a nd destruction s hould be si gned. The study 
monitor will check these records to confirm the compliance with the protocol administration schedule.
Please refer to the module describing the patient‚Äôs study treatment for more i nformation on 
treatment compliance.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277556] . All patients allocated or randomized will 
be stratified by [CONTACT_230584] y metastasis or measurable soft tissue metastasis 
to ensure there is sufficient number of patients in each group as specified in the sample size.
Investigator(s) should keep a record, the subject screening log, of subjects who entered pre-
study screening.
The Investigator(s) w ill:
[ADDRESS_277557] a unique enrollment number (i.e., E-code) using IWRS. The E-
code is sequentially issued and will be us ed to identify the subject on all study-related 
documents including the eCRF.
[ADDRESS_277558] not be assigned
Clinical Study Protocol ‚Äì 8.[ADDRESS_277559] 
be appropriately documented.
6.6 Concomitant therapy
The following treatments and the medications listed in  Appendix J are prohibited or are to be 
used with caution while patients are r eceiving AZD4635. Details for other study treatments 
are provided in the modular-specific appendix.
Table 5 Restricted medications
Medication/class of drug: Usage (including limits for duration permitted and 
special situations in which it is allowed ):
CYP1A2 inhibitors or inducers. Contribution of CYP1A2 to AZD4635 metabolism appears 
to be approximately 80%. Potent inhibitors or inducers of 
CYP1A2 should be avoided during administration of AZD4635. Refer to  Appendix J for a list of the prohibited 
medications.
Table 6 Prohibited medications
Prohibited medication/class of drug: Additional Infor mation
No other investigational therapy should be given to 
patients. No anti-cancer ag ents other than the study 
medications should be given to patients.If such agents are required for a patient, then the patient 
must first be withdrawn from the study.
Since AZD4635 is an in vitro inhibitor of BCRP 
(IC 50 6.2 ŒºM) and OAT1 (IC 50 6.6 ŒºM), there is a 
risk of DDIs with sensitive substrates of BCRP 
(both in the gut and systemically) and OAT1 (systemically). Modelling has predicted a 
substantial increase in the exposure (>2 fold) of 
certain statins (simvastatin, rosuvastatin, and atorvastatin) when co-administered with AZD4635. The use of sensitive substrates of OATP1B1/3, 
OCT1, OCT2, MATE1 and P-gp is also prohibited 
in this study.Use of potent inhibitors or inducers of BCRP and sens itive 
substrates of OATP1B1/3, OAT1, OCT1, OCT2, MATE1 
and P-gp is therefore prohibited in the current study (see 
Appendix J) .
Herbal preparations/medications are not allowed 
throughout the st udy. These herbal medications 
include, but are not limited to: St. John‚Äôs wort, 
kava, ephedra (ma huang), ginkgo biloba, 
dehydroepi[INVESTIGATOR_2119] (DHEA), yohimbe, saw 
palmetto, and ginseng.Patients should stop using these herbal medications [ADDRESS_277560] be reviewed by [CONTACT_230585].
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 45 of 1266.6.1 COVD-19 Vaccination Guidance
Authorized/approved COVID-[ADDRESS_277561] COVID-19, please consider the 
following:
!For a specific vaccine, consider the potenti al impact of its relevan t labeling information 
(i.e., ‚ÄúIndications,‚Äù ‚ÄúContraindications,‚Äù ‚ÄúWarnings and Precautions,‚Äù ‚ÄúAdverse 
Reactions‚Äù) on its use in the st udy population and individual subject.
!Please contact [CONTACT_230586]-[ADDRESS_277562] of COVID-19 vaccination on a particular study and study 
population, ensure that both the COVID-19 vaccination details (including brand name [CONTACT_230622]) is captured in eCRF as concomitant medication, and adverse reactions are reported.
6.6.2 Additional concomitant treatment
!Pre-medication will not be required, but may be utilized following the first doses of the 
investigational products. This includes management of nausea, diarrhea, and vomiting. If 
a patient has a known history of nausea and vo miting with prior therapy, it is strongly 
recommended that prophylactic anti-emetics be initiated at the start of treatment (see 
Section  [IP_ADDRESS]) .
!Blood and blood product transfusions, including platelet i nfusions, are allowed at any 
time during the study, except to meet inclusion criteria.
!Patients already taking erythropoietin at the time of screening for the study may continue 
it provided they have been taking it for more than one month at the time study treatment 
is started.
!Granulocyte colony stimulating factors (GCSFs) are permitted for use at the discretion of 
the Investigator.
!Patients should avoid corticosteroids during the study. If treatment with corticosteroids is 
indicated, the Investigator should discuss with  the Medical Monitor. If in the interest of 
patient safety the Investigator must treat the patient immediately and a discussion is not 
feasible, the Medical Monitor should be notified in writing.
!Patients may receive treatment with bisphos phonates or denosumab for the treatment of 
bone metastases.
!Patients should avoid med ications or drugs that increase r isk for seizure (e.g., tricyclic 
antidepressants, pseudoephedrine, anesthetics, amphetamines, cocaine).
!Patients may receive treatment with meges trol acetate when prescri bed for appetite 
stimulation.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 46 of 126!Patients may take low molecular weight heparin. It is recommended that patients treated 
with an anticoagulant should have their anticoagulation monitored carefully and dose
adjusted accordingly.
6.6.3 Other concomitant treatment
Other medication than that desc ribed above, which is considered necessary for the patient‚Äôs 
safety and wellbeing, may be given at the discretion of the Investigator and recorded in the appropriate sections of the eCRF.
6.[ADDRESS_277563] ice if not sp ecified differently in the study 
modules. It is generally recommended to continue observing ongoing patients at the 
frequency indicated within the study plans as de scribed in the SoA, however the assessments 
are at the Investigators' discretion based on the individual case. Restrictions regarding concomitant medications (Section  6.6) will be followed while the patient is receiving the
IP(s). Study treatment will be supplied to sites outside of the IWRS. Drug dispensation and reconciliation will be performed by [CONTACT_230587]. Serious adverse events, overdose and pregnancy will be reported after the las t dose of study treatment, for the duration 
stated in the relevant module, using a paper form.
Study will be open until last patien t treated. Final Last S ubject Last Visit will be defined as 
last patient‚Äôs treatment discontinuation.
If study drug is approved on market for use in disease under study ind ication, patients may be 
discontinued and switched to marketed product. Drug supply options can be available depending on the country and will be proposed to patient when found as best way to continue treatment by [CONTACT_230588].
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 47 of 1267 DISCONTINUATION OF TREATMENT AND PATIENT 
WITHDRAWAL
7.1 Discontinuation of study treatment
Patients that discontinue 1 study drug may remain on the study and receive other study drug(s) 
as long as they are continuing to derive clinical benefit (see Section  8.4.6) . Patients may be 
discontinued from study drug(s) in the following situations:
!Patient decision. The patient is at any time free to discontinue tr eatment, without 
prejudice to further treatment.
!Any AE that, in the opi[INVESTIGATOR_76320], contraindicates further 
dosing or meets the criteria for discontinuation as defined in the dose modification 
guidance or prescribing information for the study drug(s).
!Investigator decision or severe non-compliance with the Clinical Study Protocol
!Confirmed disease progression unless, in the opi[INVESTIGATOR_689], the p atient is st ill 
receiving clinical benefit. Patients will conti nue study treatment until objective disease 
progression, or beyond RECIST 1.[ADDRESS_277564] continue while patient continues to receive study tr eatment as per 
Section  8.1.1.
!Patients incorrectly initiated on study drug(s) (e.g., patient is determined to have met one 
or more of the exclusion criteria for study participation at study entry and continuing 
investigational therapy might constitute a safety risk)
!Patient started alternative anti-cancer therapy including another investigational agent
!Patient lost to follow-up
Note that discontinuation from study treatment is NOT the same thing as a complete 
withdrawal from the study.
See the SoA of the assigned module for data to be collected at the time of treatment 
discontinuation and follow-up and for any further evaluations that need to be completed. The 
reason for study drug and combinational agent discontinuation will be recorded in the eCRF.
7.1.[ADDRESS_277565] the 
patient¬¥s participation in the study. A patient that decides to discont inue study treatment w ill 
always be asked about the reason(s) and the presence of any AEs. The date of last intake of study treatment and the combin ational agent should be docu mented in the eCRF. All study 
treatment s hould be returned by [CONTACT_230589]-site study visit or unscheduled visit.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277566] with a relative or treating physicia n, and/or inform ation from med ical records. The approach taken 
should be recorded in the medical records. A patient who agrees to modified follow-up is not 
considered to have withdrawn consent or to have withdrawn from the study.
7.1.[ADDRESS_277567] be taken if a patient fails to return to the clinic for a required study 
visit:
!Site personnel must attempt to contact [CONTACT_230590].
!Before a patient is deemed lost to follow-up, the Investigator or designee must make 
every effort to regain contact [CONTACT_230591] (e.g. repeat telephone calls, certified letter to the patient‚Äôs last known mailing address or local equivalent methods). 
These contact [CONTACT_23526]‚Äôs medical record.
!Efforts to reach the patient should continue until the end of the study. Should the patient 
be unreachable at the end of the study, the patient should be considered to be lost to 
follow-up with unknown vital status at end of study and censored at latest follow-up 
contact.
7.3 Withdrawal from the study
A patient may withdraw from the study (e.g., withdraw consent) at any time (study drug(s) 
and assessments) at his own request, without pre judice to furthe r treatment. The reason for 
patient withdrawal will be recorded in the eCRF.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 49 of 126If a patient decides to withdraw from the study, including study treatment, the Investigator 
needs to confirm whether the patient:
!Withdraws consent to all further participation in the study including any further follow-up 
(e.g., survival contact [CONTACT_21646])
OR
!Withdraws consent from study treatment, but agrees to follow-up procedures (as defined 
in Section  7.1).
A patient who considers withdrawing from the st udy must be informed by [CONTACT_230592]-up options (e.g., telephone contact, contact [CONTACT_4490] a r elative or t reating 
physician, or inform ation from med ical records).
If the patient withdraws consent for disclosure of future information, the Sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.
If a patient withdraws consent to the use of mandatory biological samples, the samples will be 
disposed of/destroyed if possible and the action documented. If samples have already been analyzed, the Sponsor is not required to destroy the results of this research.
A patient who withdraws consent will always be asked about the reason(s) and the presence of 
any AEs. The Investigator will follow-up with patients as medically indicated.
In the event that the patient has actively withdrawn consent to the processing of his personal 
data, the vital status of the patient can be obtained by [CONTACT_230593]-up and for any furt her evaluations that need to be completed. All 
study drug should be returned by [CONTACT_102].
[ADDRESS_277568] electronic data capture (EDC) system will be used for data collection and query handling.
The Investigator will ensure the accuracy, completeness, and timeliness of the data recorded 
and the provision of answers to data queries according to the Clinical Study Agreement. The
Clinical Study Protocol ‚Äì 8.[ADDRESS_277569] reasons for screening failure, as applicable.
Procedures conducted as part of the patient‚Äôs routine clinical management (e.g., blood count) 
and obtained before signing of the ICF may be utilized for screening or baseline purposes, provided the procedures met the protocol-specified criteria and were performed within the 
time frame defined in the SoA.
The number of samples taken, as well as the volume required for each analysis, may be 
changed during the study as emerging data become available. However, the estimated total volume of blood that will be drawn from each patient in this study during screening and the first cycle of treatment w ill not exceed 300 mL (over a 1-mo nth period). Any additional 
requirements are specified within the module.
8.[ADDRESS_277570]/MRI/PET and bone scans at each scheduled disease assessment. Evaluation of objective tumor response in this study will be done using RECIST v1.1 Criteria in evaluable soft tissue disease (see  Appendix G) . Tumors will be assessed at
screening according to the module-specific SoA. Reassessment of tumors will be done by [CONTACT_230594].
PCWG3 PSA criteria (Appendix I) will also be used to evaluate response and progression. 
These criteria will be followed for determining the change in PSA levels. Prostate-specific antigen (PSA) levels in this study will be measured at screening, at the start of each new treatment cy cle, at the end of study visit, at any other timepoints indicated in the SoA, and as 
clinically indicated.
Disease progression will be deemed to have occurred if 1 or more of the following criteria is 
met:
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 51 of 126!Soft tissue disease progression as defined by [CONTACT_393] v1.1
!Bone lesion progression by [CONTACT_43877]-3 (Table 7)
!Death
Patients with PSA progression are permitted a nd encouraged to continue treatment until 
symptomatic or radiographic progression. Sites s hould monitor PSA by [CONTACT_230595] a minimum of [ADDRESS_277571]/bone scans and all imaging assessments performed for RECIST 1.[ADDRESS_277572] version 1.1 guidelines for measurable and non-measurable target lesions (TLs) and 
non-target lesions (NTLs) and the objective tumor response criteria are presented in 
Appendix G.
Baseline tumor assessments should encompass all areas of known predilection for metastases 
in the disease under evaluation and s hould additionally investigate areas that may be involved 
based on signs and symptoms of individual patients. Baseline assessments should be performed no more than [ADDRESS_277573] follow-up assessment should be initially at 6 weeks (¬±1 week) following the start of 
AZD4635 dosing and subsequent assessments will be performed every 2 cycles (every 8 weeks ¬±1 week) thereafter. Any other sites at which new disease is suspected should also be appropriately imaged. If an unscheduled assessment is performed and the patient has not progressed, every attempt should be made to pe rform subsequent assessments at the scheduled 
visits.
Categorization of objective tumor response assessment will be based on the RECIST Version
1.1 guidelines for response of soft tissue lesions: CR (complete response), PR (partial 
response), SD (stable disease), and PD (progression of disease). For patients who only have 
non-measurable TLs at baseline, categorization of objective tumor response assessment w ill 
be based on the RECIST Version 1.1 guidelines for response for NTLs: CR, PD, and Non 
CR/Non PD.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 52 of 126If the Investigator is in doubt as to whether progression has occurred, particularly with 
response to NTLs or the appearance of a new lesio n, it is advisable to continue treatment and 
reassess the patient‚Äôs status at the next schedu led assessment or sooner if clinically indicated.
To achieve ‚Äúunequivocal progression‚Äù on the basis of non-target disease, there must be an 
overall level of substantial worsening in non-target disease such that, even in presence of SD or PR in target disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest ‚Äúincrease‚Äù in the size of one or more NTLs is usually not sufficient to qualify for unequivocal PD status.
Calculation or derivation of tumor response variables
At each visit, patients will be programmatically assigned a RECIST visit response of CR, PR, 
SD or PD depending on the status of their disease compared to baseline and previous assessments.
Progression of TLs will be calculated in comparison to when the tumor burden was at a 
minimum (i.e., smallest sum of diameters previously recorded on study, nadir). In the absence 
of progression, tumor response (CR, PR, SD) will be calculated in comparison to the baseline tumor measurements obtained before starting treatment.
If a patient has had a tumor assessment that cannot be evaluated, then the patient will be 
assigned a visit response of NE, unless there is evidence of progression in which case the response will be assigned as PD.
For TL measurements, if ‚â§1/3 of the TL sizes are missing then a scaling-up rule will be 
applied as follows:
1I f‚â§1/3 of lesions recorded at baseline are missing then the results will be scaled up (based 
on the nadir sizes) to give an estimated sum of diameters and this will be used in 
calculations (this is equivalent to comparing the visit sum of diameters of the non-missing 
lesions to the nadir sum of diameters ex cluding the lesions that are missing and 
determining at what rate the lesions are changing).
2 If >1/3 of lesions recorded at baseline are missing then the TL response will be NE. 
However, if the sum of non-missing TL diameters would result in PD (i.e., if using a 
value of [ADDRESS_277574] ill increased by >20% or more 
compared to the smallest sum of diameters on study), PD takes precedence over NE.
[ADDRESS_277575] v1.1. For the analysis of objective response 
rate an ‚Äúevaluable-for-response‚Äù population will be derived and will exclude patients who do 
not have measurable disease at baseline.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277576] 
disappeared (with the exception of lymph nodes which must be <10mm to be considered non-pathological) and no new lesions have developed since baseline. A visit response of PR is defined when the sum of diameters of the TLs has decreased by 30% or more compared to baseline (with no evidence of progression) and the NTLs are at least stable with no evidence of new lesions.
In the case of SD (patients who have neither progressed nor achieved at least a PR and are 
evaluable), measurements should have met the SD criteria at least once after the study start.
When the Investigator is in doubt as to whether PD has occurred and therefore reassesses the 
patient at a later date, the date of the init ial scan should be declared as the date of progression 
if the repeat scans confirm progression.
Percentage change from baseline in tumor size will be determined for patients with
measurable disease at baseline and is derived at each visit by [CONTACT_230596].
For further details see Appendix G of this CSP.
 
 
 
It is important to follow the assessment schedule as closely as possible. Please refer to the 
Study Plan in each module and  Appendix G.
8.1.2 PCWG3 bone lesions assessment
Categorization of tumor progression of bone lesions will be based on the PCWG-3 criteria. 
Bone lesions will be assessed by [CONTACT_230597]-99 (bone scans) or PET scan. Positive hot spots on the bone scan should be considered significant and unequivocal sites of malignant disease to be recorded as metastatic bone lesions (see  Appendix G) .
The requirements for determination and confirmation of radiographic progression by [CONTACT_230598] (bone progression) or CT/MRI (soft tissue p rogression) are summarized in Table 7.CCI
Clinical Study Protocol ‚Äì 8.[ADDRESS_277577] visit after baseline (expected 
at week 6 after the start of 
AZD4635 study treatment)! 2 or more new lesions 
compared to ba seline bone 
scan.
! Requires confirmation at 
least 6 weeks later with >[ADDRESS_277578] scan after baseline! Progressive disease on CT or 
MRI by [CONTACT_393] v1.1
! Requires confirmation at 
least 4 weeks (but no more 
than 8 weeks) .
From the 2ndvisit onwards post-
baseline! [ADDRESS_277579] bone 
scan after baseline.! Progressive disease on CT or 
MRI by [CONTACT_393] v1.1
! No confirmation required.
! Requires confirmation at 
least [ADDRESS_277580], Computed tomography; MRI, Magnetic resonance imag ing; RECIST, Response Evaluation Criteria in Solid 
tumours.
 
8.1.[ADDRESS_277581] be conducted in accordance with the Laboratory Manual and the SoAs.CCI
CCI
CCI
Clinical Study Protocol ‚Äì 8.[ADDRESS_277582] to clinically 
relevant abnormalities. The la boratory results should be signed and dated and retained at the 
study center as source data for laboratory variables.
For information on how AEs bas ed on laboratory tests shoul d be recorded and reported, see 
Section  8.3.7.
Additional safety samples may be collected if clin ically indicated at the discretion of the 
Investigator. The date, time of collection and results (values, units and reference ranges) will 
be recorded on the appropriate eCRF.
Safety laboratory assessments will be performed locally at each study site laboratory by [CONTACT_230599]. Therefore, the number of samples/blood volumes is subject to site-specific change.
Laboratory values that meet the criteria for CTCAE Grade [ADDRESS_277583] changed significantly 
from baseline and are considered to be of clinical concern will be repeated/confirmed within 
7 days and followed up as appropriate.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 56 of 126Table 8 Laboratory safety variables
Hematology Clinical chemistry
Blood (B)-Hemoglobin Albumin
B-Leukocyte Alk aline phosphataseb
B-Absolute leukocyte differential c ount: ALTb
!Neutrophilsa Amylasec
!Lymphocytesa ASTb
!Monocytes Bicarbonate HCO 3d
!Basophils Calcium, total
!Eosinophils Chlorided
B-Platelet c ount Creatinined,e
Gamma glutamyltransferase (GGT)d
Coagulation Glucose
Prothrombin Time Lactate dehydroge nase (LDH)
Or Lipasec
International normalizat ion ratio (INR) and activated 
partial thromboplastin time (aPTT)Magnesiumd
Phosphate
Urinalysis Potassium
Bilirubin, bl ood, color and appearance, glucose, ketones, 
pH, protein, and specific gravitySodium
Total bilirubinb
Additional Tests Total protein
Testosterone Thyroi d stimulating hormonef
Prostate-specific antigen ( PSA) Free T4g
Hepatitis A, hepatitis B surface antigen, hepatitis C 
antibody, and HIV antibodyh, i, j,kFree T3g
Urea nitrogen
Uric acid
C-reactive protein (CRP)
a  Can be recorded as absolute counts or as percentages. Absolute counts will be calculated by [CONTACT_72987]. Total white cell count therefore has to be provided.
b  Tests for ALT, AST, alkaline phosphatase, and total bilirubin must be conducted and assessed concurrently. 
If total bilirubin is ‚â•2 √ó upper limit of normal (and no evidence of G ilbert‚Äôs syndrome), then fractionate into 
direct and indirect bilirubin.CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 57 of 126cIt is preferable that both amylase and lipase parameters are assessed. For sites where only 1 of these 
parameters is routinely measured, either lipase or amylase is acceptable.
dBicarbonate (where available), chloride, creatinine clearance, gamma glutamyltransferase, magnesium, 
testing are to be performed at baseline, on Day 1 (unless all screening laboratory clinical chemistry 
assessments are performed within 3 days prior to Day 1), and if clinically indicated.
eCreatinine clearance will be calculated by [CONTACT_230600]-Gault (using actual body 
weight).
fIf TSH is measured within 14 days prior to Day 1 (first infusion day), it does not need to be repeated at Day 
1.
gFree T3 or free T4 will only be measured if TSH is abnormal or if there is a clinical suspi[INVESTIGATOR_72912].
hHepatitis A testing will only be performed if the patient is considered symptomatic per the Investigator.
iHepatitis B testing: hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody, IgM 
hepatitis B core anti body. If he patitis B core (total) antibody testing is unavailable, then the hepatitis B core 
IgG and IgM should both be obtained instead. If a test is not locally available, then standard local practice for assessing hepatitis B status should be utilized. If screening tests are positive, a HBV-DNA test shouldbe obtained to assess infection status.
jHepatitis C anti body. If screening an tibody is positive, an HCV RNA test should be performed to assess 
infection status.
kHuman immunodeficiency virus-1 anti body.
Note: In case a patient shows an AST orALT‚â•3xULN together with TBL ‚â•2xULN please 
refer to  Appendix E ‚ÄúActions required in cases of increases in liver biochemistry and 
evaluation of Hy‚Äôs Law‚Äù for further instructions.
8.2.2 Physical examinations
A complete physical examination will be performed and include an assessment of the following: general appearance, respi[INVESTIGATOR_696], cardiovascular, abdomen, skin, head and neck (including ears, eyes, nose and throat), lym ph nodes, thyroid, musc ulo-skeletal (including 
spi[INVESTIGATOR_98243]) and neurological systems.
Physical examination will be performed at visits as specified in the module-specific SoA. 
Investigators should pay special attention to clinical signs related to previous serious illnesses. 
New or worsening abnormalities ma y qualify as AEs (see Section  8.3.7 for details).
Significant abnormal findings will be recorded in the Medical History or as an AE. 
Abbreviated symp tom-directed physical examinations will be condu cted at subseque nt visits 
post-dosing.
8.2.3 Performance status
Performance status will be asse ssed as indicated in the Study Plan figures according to ECOG 
criteria as follows:
0 = Fully active, able to carry out all pre-disease activities without restrictions
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 58 of 1261 = Restricted in physically strenuous activity but ambu latory and able to carry out work 
of a light or sedentary nature e.g., light housework, office work
2 = Ambulatory and capable of self-care, but unable to carry out any work activities. Up 
and about more than 50% of waking hours
3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours
4 = Completely disabled, cannot carry on self-care, totally confined to bed or chair.
8.2.4 Vital signs
Vital signs (pulse rate, systolic and diastolic BP, respi[INVESTIGATOR_1487], and temperature) will be 
assessed according to the screening and mo dule-specific SoA. Body weight is also recorded 
at each visit and height is recorded at screening.
!Blood pressure and pulse measurements will be assessed with a completely automated 
device. Manual techniques will be used only if an automated device is not available.
!Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_277584] 
for the patient in a quiet setting without distractions (e.g., television, cell phones).
!For the baseline BP measurement, [ADDRESS_277585] 2 diastolic readings differ by [CONTACT_726] 5 mmHg, then 
an additional reading should be obtained . For all other subsequent measurements, 
institutional standards for measuring vital signs should be followed.
If antihypertensive management is initiated during the study, more frequent BP monitoring 
should be initiated until a stable antihype rtensive regimen has been established.
Additional assessments may be performed at the d iscretion of the Investigator, if clinically 
indicated.
8.2.5 Electrocardiograms
Electrocardiograms (ECGs) will be obtained at s creening, end of treatment, and when 
clinically indicated.
Resting 12-lead ECG
Twelve-lead ECGs will be obtained after the patient has been resting supi[INVESTIGATOR_1919] 10 
minutes prior at times indicated in the screening and module-specific SoA. All ECGs s hould 
be recorded with the patient in the same physical position.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277586], if appropriate. If an abnor mal ECG finding at screening or baseline is 
considered to be clinically significant by [CONTACT_18413], it s hould be reported as a concurrent 
condition. During the study, clinically significant abnormal ECG findings not present at 
baseline should be reported as an AE (if present, the clinical signs and symptoms associated 
with the abnormal finding should be reported as the AE with the ECG abnormality given as 
explanatory information). For all ECGs details of rhythm, PR, R-R, QRS and QT intervals and an overall evaluation will be recorded on the eCRF.
8.2.6 Echocardiography or multi-gated acquisition scan
An echocardiogram (ECHO) should be performed at screening ( ‚â§14 days prior to Cycle 1 Day 
1) and within 14 days after a clinically significant ECG finding (T wave inversion/flattening). If an ECHO cannot be taken, a cardiac MRI or multi-gated acquisition (MUGA) scan to assess left ventricular ejection fraction will be c onducted. In case of any T wave abnormality, the 
ECHO, MRI, or MUGA should be repeated at the end of treatment (EOT) visit to address the question of recovery during the off-treatment period.
8.2.[ADDRESS_277587] 2 months. Other assessments to be performed are presented in the SoA in the modular-specific appendix.
8.2.8 Follow-up visits
[IP_ADDRESS] 30-day follow-up visit
A safety follow-up visit will be performed approximately 30 (¬±7) days after the study drug(s) 
is (are) permanently discontinued, unless the patient withdraws consent. The primary purpose 
of this visit is to follow-up on any AEs ongoing at the time of study treatment discontinuation and to assess any new AEs that may have occurred since discontinuation. In addition, any new medications will be recorded. This in formation can be collected by [CONTACT_648]. Any AE, 
SAE, or abnormal laboratory findings that are ongoing at the time of  study treatment 
discontinuation, or any new events within [ADDRESS_277588] be followed up to resolution or until the event becomes
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 60 of 126stable (or returns to baseline) or is unlikely to resolve further in the opi[INVESTIGATOR_684].
[IP_ADDRESS] Progression-free follow-up visits
Patients who discontinue study treatment pri or to the occurrence of objective PD will be 
followed with PSA samples and CT/MRI/PET and bone scans every 3 months (¬±1 week) from the last date of the last tumor response assessment until either: objective PD has been confirmed, withdrawal of consent, until the primary analysis DCO, or until the study or module is terminated by [CONTACT_1034].
[IP_ADDRESS] Survival follow-up
Patients will be followed every [ADDRESS_277589] review or telephone call at the Investigator‚Äôs discretion.
When required, survival calls will be made in the week following the date of DCO for the 
analysis, and if participants are confirmed to be alive or if the death date is after the DCO date, these participants will be censored at the date of DCO. When required, the status of ongoing, withdrawn (from the study), and ‚Äúlost to  follow-up‚Äù participants at the time of the 
OS analysis should be obtained by [CONTACT_230601]‚Äôs notes, hospi[INVESTIGATOR_1097], contact[CONTACT_90803]‚Äôs general practitioner and checking publicly-
available death registries. In the event that the participant has actively withdrawn consent to 
the processing of their personal data, the vital status of the participant can be obtained by [CONTACT_230602].
8.2.9 COVID-19 Testing
Tests for active COVID-19 infection may be prescribed, where appropri ate, and in accordance 
with local procedures. If a patient tests positive, their continued participation in the study and treatment with the study drugs will be  discussed with the Medical Monitor
8.3 Collection of adverse events
The Principal Investigator [INVESTIGATOR_153188].
The definitions of AEs and SAEs can be found in  Appendix B.
AEs will be reported by [CONTACT_102] (or, when a ppropriate, by a caregiver, surrogate, or the 
patient's legally authorized representative).
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 61 of 126The Investigator and any designees are responsible for detecting, documenting, and recording 
events that meet the definition of an AE or SAE. For information on how to follow-up AEs 
see Section  8.3.3.
8.3.1 Method of detecting AEs and SAEs
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the patient is the preferred method to inquire about
AE occurrences.
8.3.2 Time period and fre quency for co llecting AE and SAE infor mation
Adverse events, including SAEs, will be co llected from time of signature [CONTACT_230623] 30-day fo llow-up period, unless specified differently in 
each m odule (see module-sp ecific guidance).
All SAEs will be recorded and reported to the Sponsor or designee within 24 hours, as 
indicated in Appendix B. The Investigator will submit any updated SAE data to the Sponsor 
within 24 hours of it being available.
Investigators are not obligated to actively seek AEs or SAEs in former study patients. 
However, if the Investigator learns of any SAE, including a death, at any time after a patient‚Äôs last visit and he/she considers the event to  be reasonably related to  the study treatment or 
study participation, the Investigator may notify the Sponsor.
The methods of recording, evaluating, and a ssessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in  Appendix B.
8.3.3 Follow-up of AEs and SAEs
After the initial AE/SAE report, the Investigator is required to proactively follow each patient 
at subsequent visits/contacts. All SAEs/non-serious AEs/AEs of special interest (AESIs) (see 
module-specific guidance) will be followed until resolution, stabilization, the event is 
otherwise explained, or the patient is lost to follow-up
Any AEs that are unresolved at the patient‚Äôs last AE assessment or visit in the study will be 
followed up by [CONTACT_96770], but without further recording in the eCRF. [COMPANY_008] retains the right to request additional information for any 
patient with ongoing AEs/SAEs at the end of the study, if judged necessary.
8.3.4 Adverse event data collection
The following variables will be collected for each AE:
!AE (verbatim)
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 62 of 126!The date when the AE started and stopped
!CTCAE grade/maximum CTCAE grade
!Whether the AE is serious or not
!Investigator causality rating against the IP(s) (yes or no)
!Action taken with regard to IP(s)
!Action taken with regard to pro cedure or conco mitant medication
!Outcome
!Does the Investigator consider this AE an ImAE?
In addition, the following variables will be collected for SAEs:
!Date AE met criteria for serious AE
!Date Investigator became aware of serious AE
!AE is serious due to which criterion
!Date of hospi[INVESTIGATOR_059]
!Date of discharge
!Probable cause of death
!Date of death
!Autopsy performed
!Causality assessment in r elation to study procedure(s)
!Causality assessment in relation to other med ication
8.3.5 Causality collection
The Investigator will assess causal relationship between IP and each AE, and answer ‚Äúyes‚Äù or 
‚Äúno‚Äù to the question ‚ÄúDo you consider that there is a reasonable possibility that the event may have been related to the IP?‚Äù
For SAEs, causal relationship will also be assessed for other medication and study procedures. 
Note that for SAEs that could be associated with any study procedure the causal relationship is 
implied as ‚Äúyes‚Äù.
A guide to the interpretation of the caus ality question is found in  Appendix B to the Clinical 
Study Protocol.
8.3.6 Adverse events based on signs and symptoms
All AEs spontaneously reported by [CONTACT_230603]: ‚ÄúHave you had any health problems since the previous visit? ‚Äù, or 
revealed by [CONTACT_178557]. When co llecting AEs, 
the recording of diagnoses is preferred (when possible) to recording a list of signs and
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 63 of 126symptoms. However, if a diagnosis is known and there are other signs or symptoms that are 
not generally part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately.
8.3.7 Adverse events based on examinations and tests
The results from the protocol mandated laboratory tests and vital signs will be summarized in the clinical study report (CSR). Deterioration as compared to baseline in protocol mandated laboratory values, vital signs, ECGs, or other safety assessments should therefore only be reported as AEs if they fulfil any of the SAE criteria or are the reason for discontinuation of treatment with the IP.
If deterioration in a laboratory value/vital sign is associated with clinical signs and symptoms, 
the sign or symptom will be reported as an AE  and the associated laboratory result/vital sign
will be considered as additional information. Wherever possible the reporting Investigator will use the clinical rather than the laboratory term (e.g., anemia versus low hemoglobin value). In the absence of clinical signs or symptoms, clinically relevant deteriorations in non-mandated parameters should be reported as AE(s).
Deterioration of a laboratory value which is unequivocally due to disease progression should 
not be reported as an AE/SAE.
Any new or aggravated clinically relevant abnormal medical finding at a physical examination 
as compared with the baseline assessment will be reported as an AE unless unequivocally related to the disease under study (see Sections  8.3.9 and 8.3.10) .
8.3.8 Hy‚Äôs law
Cases where a patient shows elevations in liver biochemistry may require further evaluation 
and occurrences of AST or ALT ‚â•3xULN together with TBL ‚â•2xULN may need to be 
reported as SAEs. Please refer to Appendix E for further instruction on cases of increases in 
liver biochemistry and evaluation of Hy‚Äôs Law.
8.3.9 Disease progression
Disease progression can be considered as a worsening of a patient‚Äôs condition attributable to the disease for which the IP is being studied. It may be an increase in the severity of the disease under study and/or increases in the sym ptoms of the disease. The development of new 
or progression of existing metastasis to the prima ry cancer under study s hould be c onsidered 
as disease progression and not an AE. Event s which are unequivocally due to disease 
progression should not be reported as AEs during the study.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277590] been identified after the patient‚Äôs inclusion in th is study. They do not include metastases of the 
original cancer.
8.3.[ADDRESS_277591] dose of study drug, should be reported as follows:
!Death clearly resulting from disease progression should be communicated to the study 
monitor at the next monitoring visit and should be documented in the eCRF on the Death 
page. It should not be reported as an SAE.
!When death is not clearly due to PD of the disease under study, the AE causing the death 
should be reported to the study monitor as an SAE within 24 hours. It should also be 
documented on the Death page in the eCRF. The report should contain a comment 
regarding the co-involvement of PD, if appropriate, and should assign a single primary cause of death together with any contributory causes.
!Deaths with an unknown cause should always be reported as SAEs, but every effort 
should be made to establish a cause of death. It should also be documented in the 
Statement of Death page in the eCRF. A post-mortem may be helpful in the assessment 
of the cause of death, and if performed a copy of the post-mortem results (with translation 
of important parts into English) should be forwarded to an [COMPANY_008] representative 
within the usual time frames.
Deaths occurring after the protocol defined safety follow-up period after the administration of 
the last dose of study drug should be documented on the Death page. If the death occurred as a result of an event that started after the defined safety follow-up period and the event is considered to be due to a late onset toxicity to study drug, then it should also be re ported as an 
SAE.
8.3.[ADDRESS_277592] specific to understanding of the IP and may require close monitoring and rapid commun ication by [CONTACT_67852], or 
delegate. An AESI may be serious or non-s erious. The rapid reporting of AESIs allows 
ongoing surveillance of these events in order to characterize and understand them in association with the use of this IP.
Please refer to the modular-specific appendices for AESIs to be followed.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 65 of 1268.3.13 Safety data to be collected following the primary DCO of the study
For patients continuing to receive treatment after primary DCO and database closure, it is 
recommended that the patients continue the scheduled site visits and Investigators monitor the patient‚Äôs safety laboratory results prior to an d periodically during treatment in order to manage 
AEs in accordance with the Dose Modification and Toxicity Management Guidelines (see Section  8.4.5) . All data after the primary DCO and database closure will be recorded in the 
patient notes but, with the exception of SAEs, overdose and pregnancy, will not otherwise be 
reported for the purposes of this study.
All SAEs that occur in patients still receiving treatment (or within the [ADDRESS_277593] dose of treatment) after the primary DCO and database closure must be reported as detailed in Section  8.4.1.
8.[ADDRESS_277594] to be reported, whether or not considered causally related to the IP, or to the 
study procedure(s). All SAEs will be recorded in the eCRF and on paper forms after the final analysis DCO (16 June 2022).
If any SAE occurs in the course of the study, then Investigators or other site personnel will 
inform the appropriate [COMPANY_008] representatives within one day i.e., immediately but no 
later than [ADDRESS_277595] report SAEs and follow-up information to their responsible IRB according 
to the policies of the responsible IRB. For fatal or life-threatening AEs for which important or relevant information is missing, active follow-up is undertaken immediately.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 66 of 126[COMPANY_008], or their represe ntatives, will provide Regulatory Authori ties, Ethics Committees, 
and Principal Investigators with clinical safety updates/reports according to localrequirements.
Full details of the AE reporting process are provided in the Safety Handling Plan for the st udy.
For further guidance on the definition of a SAE, see  Appendix B of the core Clinical Study 
Protocol.
8.4.[ADDRESS_277596] has received any study drug. Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs. All pregnancies occurring after the final analysis DCO w ill 
be recorded on paper forms.
[IP_ADDRESS] Paternal exposure to AZD 4635
Information on the pregnancy of a patient‚Äôs partner must be obtained directly from the 
patient‚Äôs partner. Therefore, prior to obtaining information on the pregnancy, the Investigator must obtain the consent of the patient‚Äôs partner.
Pregnancy of a patient‚Äôs partner is not considered to be an AE. However, outcome of all 
pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, 
or congenital abnormality) occurring from the fi rst date of dosing until 3 months (unless 
specified differently in relevant module) after dosing should, if possible, be followed up and documented.
Male patients should u se condoms with female partners during the study and for 12 weeks (3 
months or as specified in relevant module) after the last dose of AZD4635, and refrain from 
donating sperm from the start of dosing until 24 weeks (6 months) after discontinuing study treatment. If not done previously, storage of sperm prior to receiving AZD4635 will be advised to male patients with a desire to  have children. See relevant module for module-
specific information.
It is not currently known whether AZD4635 affects fer tility in humans.
[COMPANY_008] s hould be notif ied of any pregnancy that occurs in partners of male patients 
during participation in studies of AZD4635.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 67 of 1268.4.3 Overdose
Any dose of AZD4635 in excess of 110% of the dose per cycle of treatment specified 
according to the protocol will constitute an ove rdose, unless associated with an AE, in which 
case any dose in excess of the dose specified according to the protocol will constitute an overdose. There is currently no known antidote to AZD4635, and the treatment of overdose should be supportive for the underlying symptoms. Please refer to relevant module to see module-specific overdose guidance. All overdoses as specified above, occurring after the 
final analysis DCO will be recorded on paper forms.
If an overdose of an [COMPANY_008] study drug occurs in the course of the study, then the 
Investigator or other site personnel will inform appropriate [COMPANY_008] representatives 
immediately, or no later than 24 hours of when he or she becomes aware of it.
The designated [COMPANY_008] representative works with the Investigator to ensure that all 
relevant information is provided to the [COMPANY_008] Patient Safety data entry site.
!For overdoses associated with a SAE, the sta ndard reporting timelines apply (see Section 
8.3.2) . For other overdoses, reporting must occur within 30 days.
8.4.4 Medication error
If an medication error occurs in the course of the study, then the Investigator or other site 
personnel will inform the appropriate [COMPANY_008] representatives within 1 day i.e., 
immediately but no later than 24 hours of when he or she becomes aware of it.
The designated [COMPANY_008] representative works with the Investigator to ensure that all 
relevant information is completed within 1 calendar day (initial f atal/life-thr eatening or 
follow-up fatal/life-threatening) or 5 calendar days (other serious initial and follow-up) if there is an SAE associated with th e medication error (see Section 8.3.2) and within 30 days 
for all other medication errors.
The definition of a medication error can be found in Appendix B.
8.4.5 Management of AZD4635-related toxicities
AZD4635 management and discontinuation guidelines for non-hematologic tox icities (except 
hypertension) are shown in  Table 9. Intrapatient dose re-escalation is not permitted.
AZD4635 dose reduction guidelines are in Section 6 of the study-specific modules.
If a patient experiences a clinically significant and/or unacceptable toxicity not attributable to 
the disease or disease-related processes under investigation, dosing will be interrupted or the dose reduced and supportive therapy administered, as required. If the toxicity resolves or 
reverts to ‚â§ CTCAE Grade 2 within 2 treatment weeks and the patient is showing clinical
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 68 of 126benefit per the Investigator, treatment with AZD4635 may be restarted. If the toxicity does 
not resolve to ‚â§ CTCAE Grade 2 after 2 weeks of treatment then the patient should be 
withdrawn from the study and observed until resolution of the toxicity. Maximum drug holiday allowed is 2 weeks for non-immune-mediated toxicity.
Table 9 AZD4635 dose modifications and discontinuation criteria for non-
hematologic toxicities (except hypertension)
NCI CTCAE Toxicity Grade Action
Grade 1 or 2 None required
Grade 3 or 4 and/or clinically significantaHold AZD4635
Toxicity resolved to Grade 1, Grade 2, or bas eline
<14 days
Toxicity remains Grade 3 to 4 or is clinically 
significanta>14 daysRestart AZD4635 at 1 dose level reduction
Discontinue AZD4635
Recurrence of Grade 3 Reduce 1 more dose level if module-specific 
guidance allows or if not discontinue AZD4635
Recurrence of Grade 3 cardiac eventaDiscontinue AZD4635
Recurrence of Grade 4 Discontinue AZD4635
a  Includes significant change in CK/CK-mb ratio (relative index >5%), increases in heart rate of +25 bpm (up 
to 100 to 125 bpm) for more than 24 hours or increase in heart rate >125 bpm for more than 12 hours), QTc 
prolongation >500 ms.
[IP_ADDRESS] Hypertension
Treatment of hypertension and goal BP will be in accordance with international guidelines. 
AZD4635 dose reduction and discontinuation guidelines for the management of hypertension are shown in  Table 10. Details on daily management of BP are provided in Section  8.2.4.
Patients taking antihypertensive medications will take and record BP readings twice-daily 
while at home (recommended [ADDRESS_277597]-dose) for at least the first 3 weeks after starting study drug. Twice-daily monitoring should be re-implemented after any AZD4635 
hold/dosing delay for [ADDRESS_277598] 3 weeks of study treatment to ensure that BP guidelines are being correctly followed.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 69 of 126Table 10 AZD4635 dose modifications and discontinuation criteria for 
management of hypertension
Event severity Antihypertensive 
therapyBP monitoring AZD4635 dose modification
Systolic BP 150 to 159 mm 
Hg or diastolic BP90 to 99 mm Hg; 
medical intervention 
indicated;
recurrent or persistent ( ‚â•24 
hrs); symptomatic increase 
by >20 mm Hg (diastolic) or 
to >150/90 mm Hg if 
previously within normal limitsInitiate/escalate 
antihypertensive 
medication as per local guidelines.
BP goal and the choice 
of the antihypertensive 
drug will be 
individualized for each patient.Increase 
frequency of 
monitoring until stabilized to BP<150/90 mmHgNone
Grade 3
(systolic BP >=160 mm Hg 
or diastolic BP >=100 mm 
Hg); medical intervention 
indicated; more than one 
drug or more intensive therapy than previously used indicatedInitiate or maximize BP 
therapy as per local guidelines.
Consider consult with a 
BP management specialistIncrease 
frequency of monitoring until 
stabilized to BP
<150/90 mmHgMay continue AZD4635 with 
optimization of antihypertensive management 
unless persistent BP-related 
clinical symptoms.
Hold AZD4635 if BP is not 
decreased to grade 2 within 48 hours after optimum therapy is instituted.
If BP is reduced to baseline or 
Grade 1 within 14 days and considered stable, AZD4635 may be resumed at original
dose.
Discontinue AZD4635 if BP 
does not resolve to Grade 1 within 14 days.
Discontinue AZD4635 if BP 
systolic ‚â•180 mmHg and/or 
diastolic ‚â•110 mmHg)
Recurrence of Grade 3: 
Discontinue study drug.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 70 of 126Table 10 AZD4635 dose modifications and discontinuation criteria for 
management of hypertension
Event severity Antihypertensive 
therapyBP monitoring AZD4635 dose modification
Grade 4
Life-threatening 
consequences
(e.g., malignant hypertension, 
transient or permanent neurologic deficit, hypertensive crisis); urgent intervention indicatedInitiate treatment per 
local guidelines, including 
hospi[INVESTIGATOR_059], ICU 
management, and IV therapy as necessaryDiscontinue AZD4635
[IP_ADDRESS] Nausea a nd vomiting
If a patient has a known history of nausea and vomiting with prior therapy, it is strongly 
recommended that prophylactic anti-emetics be initiated at the start of treatment. They should 
continue as required thereafter, in accordance with local treatment practice guidelines.
Additionally, AZD4635 capsules can be taken with a light meal/snack which may improve tolerability (i.e., [ADDRESS_277599] or a couple of biscuits).
As per international guidance on anti-emetic use in cancer subjects (ESMO, NCCN), 
generally a single agent anti- emetic s hould be consid ered (e.g., dopamine r eceptor antagonist, 
antihistamines or dexamethasone).
8.4.6 Duration of therapy
Patients may continue to receive AZD4635 and/or other combination therapeutic agent as long as they are continuing to show clinical benefit, as judged by [CONTACT_737], and in the absence of discontinuation criteria.
8.5 Pharmacokinetics
Venous blood samples (2mL each) for determination of concentrations of AZD4635 and its 
metabolites in plasma will be taken  in this study for all modules.
Please refer to the module-specific a ppendix for AZD4635 co llection time points.
8.5.[ADDRESS_277600] 
sites on behalf of [COMPANY_008], using an appropriate bioanalytical method. Full details of the analytical method used will be described in a separate bioanalytical report.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277601] at the time of r eceipt by 
[CONTACT_115009].
In addition, the PK samples may be subjected to furt her analyses in order to further investigate 
the presence and/or identity of drug m etabolites. Any results from such analyses will be 
reported separately from the CSR, but known metabolites will be reported in the CSR.
Incurred sample reproducibility analysis, if any, will be performed alongside the bioanalysis 
of the test samples. The results from the ev aluation will not be reported in the CSR but 
separately in a Bioanalytical Report.
8.5.2 Storage and destruction of pharmacokinetic samples
Pharmacokinetic (PK) samples will be disposed of after the bioanalytical report finalization or 6 months after issuance of the draft bioan alytical report (whichever is earlier), unless 
requested for future analyses.
Pharmacokinetic samples may be disposed of or anonymized by [CONTACT_76435]. Additional analyses 
may be conducted on the anonymized, pooled PK samples to further evaluate and validate the 
analytical method. Any results from such analyses may be reported separately from the CSR.
8.6
8.7
8.7.1
 
 
 
 
 
8.7.2
 
 
 
 
 CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 73 of 1268.8.2
 
 
 
 
 
 
 
8.8.3
 
 
 
 
8.8.4
 
 
 CCI
CCI
CCI
CCI
Clinical Study Protocol ‚Äì 8.[ADDRESS_277602] ical Analysis Plan w ill be developed and finalized before database 
lock and will describe the patient populations to be included in the analyses (performed by [CONTACT_230604]/or a third party), and procedures for accounting for missing, unused, and spurious data. This section is a s ummary of the planned statist ical analyses of the primary and 
secondary endpoints. Any deviations from this plan will be reported in the clinical study 
report. Final analysis of all endpoints specified in this protocol will use all data up to and 
including the date of final analysis DCO.
The primary aim of the study is to assess the efficacy , safety, and tolerability of multiple study 
drugs in patients with prostate cancer.
9.[ADDRESS_277603] udy and consists of multiple single arm cohorts 
under a m odular protocol. There are no plans to for mally compare between the cohorts and 
this is not part of the study objectives. The aim is to identify treatment(s) to take forward into 
further trial(s). As such, there are no formal statistical hypothesis tests associated with the study objectives; statistical analysis of all study endpoints is descriptive.
The primary efficacy endpoint is PSA decline from baseline measure ‚â•50% (PSA50) and 
overall response rate (ORR) per RECIST v1.1. The PSA endpoint will be used to define the sample size for patients with and without measurable disease at baseline.
In Module 1, 2, and 3 (if conducted) there will be approximately [ADDRESS_277604] measurable disease at baseline 
in each module.CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 75 of 126In Module 1, 2, and 3 (if conducted) approximately 30 patients with and without measurable 
disease at baseline will be assessed for PSA50 in each module.  
 
 
In Module 1, 2, and 3 (if conducted), approximately 20 patients with measurable disease at 
baseline will be assessed for ORR in each module.  
 
 
 
 
 
 
If any of the required patients for PSA and/or ORR are not evaluable for PSA response or 
tumor response, respectively, they may be replaced at the Sponsor's discretion.
9.3 Populations for analyses
For purposes of analysis, the following populations are defined:
Population Description
Pharmacokinetics Dosed p atients with at least 1 reportable PK concentr ation
Tumor response Dosed patients with a baseline tumor assessment, and measurable disease at 
baseline.
PSA response Dosed p atients with an abnormal baseline PSA data ( ‚â•1ng/mL)
Evaluable for efficacy Do sed patients with a baseline tumor assessment.
Safety analysis set All patients who received at least [ADDRESS_277605] ill be re ported in 
the study result listings. Important deviations  will be listed and summarized in the CSR.CCI
CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 76 of 1269.4 Statistical analyses
All analyses will be reported per module.
9.4.1 Definition of endpoints
To meet the objectives for this study, data for the following endpoints will be collected:
!PSA response (Primary)
!Overall Response Rate (Pr imary)
!AZD4635 and metabolites PK concentrations (Secondary)
!Durvalumab and oleclumab PK concentrations (Secondary)Tumor response (Sec ondary)
‚àÄDOR
!Overall survival (OS) (Sec ondary)
!Radiological progression-free survival (rPFS) (Sec ondary)
!
!
!Immunogenicity (ADA) (Secondary)
!Safety and Tolerability
‚àÄAEs/SAEs
‚àÄPhysical exam and vitals
‚àÄClinical chemistry/ hematology par ameters
!
!
9.4.2 Demographic data
Characteristics of the patients, including medical history and disease characteristics at 
baseline, will be listed for each patient and summarized by [CONTACT_230605].
9.4.3 Exposure
Exposure to IPs, i.e., total amount of study drug received, will be listed for all patients.
Reasons for discontinuation of IP will be listed including the study day of treatment 
discontinuation and will be summarized by [CONTACT_230606].
Total exposure and total time on study (date of last dose minus date of first dose) will be 
summarized by [CONTACT_716]: mean, standard deviation, minimum, maximum, median and number of observations. In addition, the number and percentage of patients with at least one dose interruption and at least one dose reduction will be presented separately for the initialCCI
CCI
CCI
CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 77 of 126period of evaluability (defined as 21 days) and for any time following this initial period of the 
study.
Relative Dose Intensity (RDI) will be calculated, and is defined as follows:
!RDI = 100% * d/D, where d is the actual cumulative dose delivered up to the earlier of 
progression (or a censoring event) or the actual last day of dosing and D is the intended 
cumulative dose up to the earlier of progression (or a censoring event) or the actual last 
day of dosing plus the protocol defined post-dose rest period.
9.4.4 Efficacy analyses
PSA response
PSA response is defined as the proportion of patients achieving a ‚â•50% decline from baseline 
to the lowest post-baseline PSA results, confirmed by a second consecutive PSA assessment at 
least 3 weeks later. Ignore early rises (before 12 weeks) in determining PSA response.
‚àÄA patient will be regarded as having a single PSA visit response if their PSA level at 
any post-dose visit is reduced by 50% or more compared with baseline
‚àÄA patient will be regarded as having a confirmed PSA response if they have a 
reduction in PSA level of 50% or more compared with baseline that is confirmed at the next assessment at least 3 weeks later (i.e., decrease relative to baseline of at least 
50% documented on [ADDRESS_277606] 3 weeks apart).
PSA progression
If there is a PSA decline from baseline, progression is defined as the date of the first PSA 
increase that is both ‚â•25% and‚â•2 ng/mL above the nadir and which is confirmed by a second 
value ‚â•3 weeks later, even if within 12 weeks.
If there is no PSA decline from baseline, progression is defined as a ‚â•25% increase and ‚â•2 
ng/mL increase from baseline beyond 12 weeks.
The proportion of patients achieving a PSA res ponse and patients with a confirmed PSA 
response will be presented with 95% CI. The best PSA percentage change from baseline and 
the percent change from baseline in PSA levels at 12 weeks will be summarized and graphed. Waterfall plots (bar plots), and spi[INVESTIGATOR_230563] (individual line plots of percent change from baseline over time) will be produced.
Tumor response
Tumor response data will be summarized for dosed patients with measurable disease at 
baseline and separately for dosed patients that had measurable or non-measurable disease at baseline.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 78 of 126Tumor response data will be listed and summarized by [CONTACT_2715], if appropriate, using the 
following response categories: CR, PR, SD, PD, and not evaluable (NE).
Best objective response and ORR will be summarized. Percentage change from baseline in 
tumor size will be determined for patients with measurable disease at baseline and is derived at each visit by [CONTACT_230607].
Waterfall plots (bar plots), and spi[INVESTIGATOR_230563] (individual line plots of percent change from 
baseline over time) indicating the percenta ge change from baseline i n sum of the diameters of 
TLs will be produced by [CONTACT_15994].
Duration of response (DoR) will be defined as the time from the date of first documented 
response (which is subsequently confirmed using RECIST v1.1) until date of documented progression or death in the absence of disease progression. The end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing towards the first visit that was PR or CR that was subsequently confirmed.
If a patient does not progress following a response, then their duration of response will use the 
PFS censoring date as the date at which that subject is censored for DoR.
 
Radiological progression-free survival (rPFS)
Progression-free survival is defined as the time interval from the first dose of AZD4635 until 
the date of objective disease progression or death (by [CONTACT_72999]) 
regardless of whether the patient withdraws from treatment or receives another anti-cancer 
therapy prior to progression. Patients who have not progressed (defined as CR, PR or SD by [CONTACT_393] v1.1 for soft tissue disease, or non-PD for bone disease, see  Appendix G) at the time 
of analysis will be censored at the time of the last evaluable RECIST assessment or bone scan.
However, if the patient progresses or dies after [ADDRESS_277607] v1.1 or bone scan assessment prior to the 2 missed visits. If a patients has an assessment for soft tissue disease (MRI/CT) but not for bone disease (bone scan), or vice versa, then this will count as a missed assessment. If the patient has no evaluable post-baseline RECIST v1.1 or bone scan assessment they will be censored at 1 day unless they die within 2 visits of baseline (in which case their date of death 
will be used).
Progression-free survival will be derived based on scan/assessment dates not the scheduled 
visit dates. If RECIST v1.1 assessments/bone scans contributing toward a particular visit are performed on different dates then the date of progression will be determined based on theCCI
Clinical Study Protocol ‚Äì 8.[ADDRESS_277608] was known to be alive.
Note: Survival calls will be made in the week following the date of DCO for the analysis, and 
if subjects are confirmed to be alive or if the death date is after the DCO date these subjects will be censored at the date of DCO. See Section 7for methods that can be used to determine 
status of subjects who withdraw consent or are lost to follow-up.
9.4.[ADDRESS_277609] 1 dose of study drug will be included in the assessment of the safety profile (safety analysis set).
Data from all cycles of initial treatment w ill be presented as described in the Statistical 
Analysis Plan. Adverse events will be listed individually by [CONTACT_230608]. For patients who have a dose modification, all AEs (due to drug or otherwise) will be assigned to the initial dose group. The number of patients experiencing each AE will be summarized by [CONTACT_230609] (MedDRA) system organ class, MedDRA 
preferred term, and CTCAE grade. The number and percentage of patients with AEs in 
different categories (e.g., causally related, CTCAE Grade ‚â•3, etc.) will be summarized by 
[CONTACT_7169], and events in each category will be further summarized by [CONTACT_230610] m, by [CONTACT_7169]. Serious AEs will be summarized separately if 
a sufficient number occur.
Any AE occurring before the first dose of IP (i.e., before study Day 1) will be included in the 
data listings, but will not be included in the summary tables of AEs.
Any AE occurring within the defined follow-up period (see m odules for specific time period) 
after discontinuation of IP will be included in the AE summaries. Any AEs in this period that occur after a patient has received further therapy for cancer (following discontinuation of IP) will be flagged in the data listings. Adverse events occurring after the 30-day or 90-day follow-up period after discontinuation of IP will be listed separately, but not included in the summaries.
Hematology, clinical chemistry, vital signs, ECG data, ECHO/MUGA, demographic data, 
medical histories, and concomitant medications will be listed individually by [CONTACT_230611]. For all laboratory variables, which are included in the current version of
Clinical Study Protocol ‚Äì 8.[ADDRESS_277610] time, con centration or shift 
plots. Appropriate scatter plots will also be considered to investigate trends in parameters compared to baseline.
9.4.6 Other analyses
The analysis of the secondary endpoints PK, known metabolites and immunogenicity will be reported in the CSR.  
9.4.7 COVID-19 analyses
Refer to the Statistical Analysis Plan for details regarding COVID-19.
9.5 Interim analyses
No formal interim analysis is planned.CCI
CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 81 of [ZIP_CODE] REFERENCES
Antonia et al. 2017
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after 
chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-29.
Brahmer et al. 2015
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab 
versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 
Jul 9; 373(2):123-35.
Bray et al. 2018
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 
2018: GLOBOCAN estimates of incidence a nd mortality worldwide for 36 cancers in 185 
countries. CA Cancer J Clin. 2018;68:394-424.
Eisenhauer et al. [ADDRESS_277611] R, et al. New response 
evaluation criteria in solid tumors: revis ed RECIST guideline (Version 1.1). Euro J Cancer.
2009;45:228-47.
Larkin et al. 2015
Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipi[INVESTIGATOR_230564]. N Engl J Med. 2015 Sept;373(13):1270-1.
Le et al. 2015
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in 
tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-20.
McDermott et al. 2015
McDermott DF, Drake CG, Sznol M, Choueiri RK, Powderly JD, Smith DC, et al. Survival, 
durable response, and long-term safety in patien ts with previously treated advanced renal cell 
carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013-20.
Robert et al. 2015
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus 
ipi[INVESTIGATOR_15172]. N Engl J Med. 2015;372(26):2521-32.
Ryan et al. 2013a
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in 
metastatic prostate cancer without previous ch emotherapy. N Engl J Med. 2013;368:138-48.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 83 of [ZIP_CODE] SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
Appendix A Regulatory, ethical and study oversight considerations
A 1 Regulatory and ethical considerations
This study will be conducted in accordance with the protocol and with the following:
!Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines
!Applicable ICH Good Clinical Practice (GCP) Guidelines
!Applicable laws and regulations
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents 
(e.g., advertisements) must be submitted to an IRB/IEC by [CONTACT_6661]/IEC before the study is initiated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study patients.
The Investigator will be responsible for the following:
!Providing wri tten su mmaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/IEC
!Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures
!Providing oversight of the conduct of the study at the site and adherence to requirements 
of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical 
studies (if applicable), and all other applicable local regulations
The study will be performed in accordance with the [COMPANY_008] policy on Bioethics and 
Human Biological Samples.
Regulatory Reporting Requirements for SAEs
!Prompt notification by [CONTACT_46352] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.
!The Sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study intervention under clinical
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 84 of 126investigation. The Sponsor will comply with country-specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRBs, and Investigators.
!For all studies except those utilizing medical devices Investigator safety reports must be 
prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local 
regulatory requirements and Sponsor policy and forwarded to Investigators as necessary.
!An Investigator who receives an Investigator safety report describing a SAE or other 
specific safety information (e.g., summary or listing of SAEs) from the Sponsor will review and then file it along with the Investigator‚Äôs Brochure and will notify the IRB, if 
appropriate according to local requirements.
A 2 Financial disclosure
Investigators and sub-Investigators will provide the Sponsor with sufficien t, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate Regulatory Authorities. Investigators 
are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.
A 3 Informed consent process
The Investigator or his/her representative will explain the nature of the study to the patient or his/her legally authori zed representative and answer all questions regarding the study.
Patients must be informed that their particip ation is voluntary. Patients or their legally 
authorized representative will be required to sign a statement of informed consent that meets the requirements of [ADDRESS_277612] (HIPAA) requirements, where applicable, and the IRB/IEC or study center.
The medical record must include a statement that written informed consent was obtained 
before the patient was enrolled in the study and the date the wri tten consent was ob tained. 
The authorized person obtaining the informed consent must also sign the ICF.
Patients must be re-consented to the most current version of the ICF(s) during their 
participation in the study.
A copy of the ICF(s) must be provided to the pa tient or the patient‚Äô s legally authorized 
representative.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 85 of 126 
 
If a patient‚Äôs partner becomes pregnant during or within 3 months (or as indicated in module-
specific appendix) after the study, the partner is asked to sign the "Adult Study ICF for Pregnant Partners of Study Patients" and provide information about the pregnancy accordingly.
The ICF will contain a separate section that addresses the use of remaining mandatory 
samples for optional exploratory research. The Investigator or authorized designee will explain to each patient the objectives of the exploratory research. Patients will be told that they are free to refuse to participate and may withdraw their consent at any time and for any reason during the storage period. The patient will give a separate agreement to allow any 
remaining specimens to be used for exploratory research. Patients who decline to participate 
in this optional research will indicate this in the ICF. If a patient withdraws consent to the use of donated biological samples, the samples will be disposed of/destroyed, and the action 
documented. If samples already have been analyzed at the time of the request , [COMPANY_008] 
will not be obliged to destroy the results of this research.
A 4 Data protection
Each patient will be assigned a unique identifier by [CONTACT_1034]. Any patient records or data 
sets transferred to the Sponsor will contain only the identifier; patient names or any information which would make the patient identifiable will not be transferred.
The patient must be informed that his/her personal study-related data will be used by [CONTACT_19490]. The level of disclosure must also be explained to the patient.
The patient must be informed that his/he r medical records may b e examined by [CONTACT_230612] S ponsor, by 
[CONTACT_6667]/IEC members, and by [CONTACT_230613].
A 5 Committees structure
The safety of all [COMPANY_008] clinical studies is closely monitored on an ongoing basis by [CONTACT_178560]. Issues identified will be 
addressed; for instance this could involve amendments to the Clinical Study Protocol and letters to Investigators.CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 86 of 126A 6 Dissemination of clinical study data
A description of this clinical trial will be available on http://astrazenecaclinicaltrials.com and 
http://www.clinicaltrials.gov as will the summary of the main study results when they are 
available. The clinical trial and/or summary of main study results may also be available on other websites according to the regulations of the countries in which the study is conducted.
A 7 Data quality assurance
All patient data relating to the study will be recorded on printed or eCRF unless transmi tted to 
the Sponsor or designee electronically (e.g., laborat ory data). The Investig ator is responsible 
for verifying that data entries are accurate and correct by [CONTACT_46388].
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.
The Investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide  direct access to source data documents.
The Sponsor or designee is responsible for the data management of this study including 
quality checki ng of the data.
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of patients are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including signed ICFs, pertaining to the conduct of this study must 
be retained by [CONTACT_13177] 15 years after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No  records may be 
transferred to another location or party without written notification to the Sponsor.
A 8 Source documents
Source documents provide eviden ce for the existence of the patient and substantiate the 
integrity of the data collected. Source documents are filed at the Investigator‚Äôs site.
Data reported on the eCRF that are transcribed from source documents must be consistent
with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 87 of 126Definitions of what constitutes source dat a can be found in the clinical trial agreement.
A 9 Study and site closure
The Sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the Sponsor. The study may be stopped if, in the judgment of [COMPANY_008], trial subjects are placed at undue risk because of clinically significant findings that:
!meet individual st oppi[INVESTIGATOR_230565]
!are assessed as caus ally related to study drug,
!are not considered to be consistent with continuation of the study
Regardless of the reason for termination, all data available for the subject at the time of 
discontinuation of follow-up must be recorded in the CRF. All reasons for discontinuation of 
treatment must be documented.
In terminating the study, the Sponsor will ensure that adequate consideration is given to the 
protection of the subjects‚Äô interests
Study sites will be closed upon study completion. A study site is considered closed when all 
required documents and study supplies have been collected and a study site closure visit has 
been performed.
The Investigator may initiate study site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by [CONTACT_216594]:
!Failure of the Investigator to comply with t he protocol, the requirements of the IRB/IEC 
or local health authorities, the Sponsor's procedures, or GCP guidelines
!Inadequate recruitment of participants by [CONTACT_737]
!Discontinuation of further study intervention development
A [ADDRESS_277613] proprietary information and to provide 
comments.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277614] editorial and ethical practice, the Sponsor will generally support publication of multicentre studies only in their entirety and not as individual site data. In this case, a coordinating Investigator [INVESTIGATOR_12992].
Authorship will be determined by [CONTACT_175067].
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 89 of 126Appendix B Adverse event definition s and additional safety information
B 1 Definition of adverse events
An adverse event (AE) is the development of any untoward medical occurrence in a patient or 
clinical study patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g. an abnormal laboratory finding), symptom (for example nausea, chest pain), or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
The term AE is used to include both serious and non-serious AEs and can include a 
deterioration of a pre-existing medical occurrence. An AE may occur at any time, including run-in or washout periods, even if no study treatment has been administered.
B 2 Definitions of serious adverse event
A serious adverse event (SAE) is an AE occurring during any study phase (i.e., run-in, treatment, washout, follow-up), that fulfills one or more of the following criteria:
!Results in death
!Is immediately life-thr eatening
!Requires in-patient hospi[INVESTIGATOR_103296]
!Results in persistent or signi ficant disabilit y or incapacity.
!Is a congenital a bnormality or birth defect
!Is an important medical event that may jeopardize the patient or may require medical 
treatment to prevent one of the outcomes listed above.
B 3 Life- threatening
‚ÄòLife-threatening‚Äô means that the patient was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the patient‚Äôs death. ‚ÄòLife-threatening‚Äô does not mean that had an AE occurred in a more severe form it might have caused death (e.g., hepatitis that resolved without hepatic failure).
B 4 Hospi[INVESTIGATOR_230566] a serious AE, although the reasons 
for it may be (e.g., bronchospasm, laryngeal edema). Hospi[INVESTIGATOR_2144]/or surgical 
operations planned before or during a study are not considered AEs if the illness or disease 
existed before the patient was enrolled in the study, provided that it did not deteriorate in an unexpected way during the study.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277615] drug does not mean that it is an importan t medical event; medical 
judgment must be used.
!Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatment
!Hepatotoxicity cause d by [CONTACT_76475] ( acetaminophen) overdose requiring tr eatment with 
N-acetylcysteine
!Intensive treatment in an emergency r oom or at home for allergic bronchospasm
!Blood dyscras ias (e.g., neut ropenia or an emia requiring blood transfusion, etc.) or 
convulsions that do not result in hospi[INVESTIGATOR_059]
!Development of drug dependency or drug abuse
B 6 Intensity rating scale:
The grading scales found in the revised Nation al Cancer Institute CT CAE latest version will 
be utilized for all events with an assigned CTCAE grading. For those events without assigned 
CTCAE grades, the recommendation in the CTCAE criteria that converts mild, moderate and 
severe events into CTCAE grades should be used. A copy of the CTCAE can be downloaded from the Cancer Therapy Evaluation Progra m website (http://ctep.cancer.gov). The applicable 
version of CTCAE should be described clearly.
It is important to distinguish between serious and severe AEs. Severity is a measure of 
intensity whereas seriousness is defined by [CONTACT_73010]  B 2. An AE of severe 
intensity need not necessarily be considered serious. For example, nausea that persists for 
several hours may be consider ed severe nausea, but not a SAE unless it meets the criteria 
shown in Appendix B2 . On the other hand, a stroke that results in only a limited degree of 
disability may be considered a mild st roke but would be a SAE when it satisfies the cr iteria 
shown in Appendix  B 2.
B 7 A Guide to Interpreting the Causality Question
When making an assessment of causality consider th e following factors when deciding if there 
is a ‚Äòreasonable possibility‚Äô that an AE may have been caused by [CONTACT_33641].
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 91 of 126!Time Course. Exposure to suspect drug. Has the patient actually received the suspect 
drug? Did the AE occur in a reasonable temporal relationship to the administration of the 
suspect drug?
!Consistency with known drug profile. Was the AE consistent with the previous 
knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same 
pharmacological class? Or could the AE be anticipated from its pharmacological 
properties?
!De-challenge experience. Did t he AE resolve or improve on st oppi[INVESTIGATOR_72918]?
!No alternative cause. The AE cannot be reasonably explained by [CONTACT_230614], other drugs, other host or environmental factors.
!Re-challenge experience. Did the AE reoccur if the suspected drug was reintroduced 
after having been stopped? [COMPANY_008] would not normally reco mmend or support a re-
challenge.
!Laboratory tests. A specific laboratory investigation (if performed) has confirmed the 
relationship.
In difficult cases, other factors could be considered such as:
!Is this a recognized feature of overdose of the drug?
!Is there a know n mechanism?
Causality of ‚Äòrelated‚Äô is made if following a review of the relevant data, there is evidence for a 
‚Äòreasonable possibility‚Äô of a causal relationship for the individual case. The expression 
‚Äòreasonable possibility‚Äô of a causal relationship is meant to convey, in general, that there are 
facts (evidence) or arguments to suggest a causal relationship.
The causality assessment is  performed based on the available data including enough 
information to make an informed judgment. Wit h limited or insufficient information in the 
case, it is likely that the event( s) will be assessed as ‚Äònot related‚Äô.
Causal relationship in cases where the disease under study has deteriorated due to lack of 
effect should be classified as no reasonable possibility.
B 8 Medication Error
For the purposes of this clinical study a med ication e rror is an unintended failure or mistake in 
the treatment process for an [COMPANY_008] study drug that either causes harm to the participant 
or has the potential to cause harm to the participant.
A medication error is not lack of efficacy of the drug, but rather a human or process r elated 
failure while the drug is in control of the study site staff or participant.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 92 of 126Medication error includes situations where an e rror.
!occurred
!was identified and intercepted before the participant received the drug
!did not occur, but circumstances were r ecognize that could have led to an e rror
Examples of events to be reported in clinical studies as medication errors:
!Drug name [CONTACT_2976]
!Dispensing error e.g. med ication prepared incorrectly, even if it was not actually given to 
the participant
!Drug not administered as indicated, for example, wrong route or wrong site of 
administration
!Drug not taken as indicated e.g. tablet dissolved in water when it should be taken as a 
solid tablet
!Drug not stored as instructed e.g. kept in the fridge when it should be at room 
temperature
!Wrong participant received the med ication (excluding IVRS/IWRS errors)
!Wrong drug administered to participan t (excluding IV RS/IWRS errors)
Examples of events that do not require reporting as medication e rrors in clinical studies:
!Errors related to or resulting from IVRS/IWRS - including those which lead to one of the 
above listed events that would otherwise have been a medication error
!Participant accidentally missed drug dose(s) e.g. forgot to take med ication
!Accidental overdose (will be captured as an ove rdose)
!Participant failed to return unused medication or empty packaging
!Errors related to background and rescue medication, or standard of care medication in 
open-label studies, even if an AZ product
Medication errors are not regarded as AEs but AEs may occur as a consequence of the 
medication error.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 93 of 126Appendix C Handling of Human Biological Samples
C 1 Chain of custody of biological samples
A full chain of custody is maintained for all samples th roughout their lifecycle.
The Investigator at each center k eeps full traceability of collected biological s amples from the 
patients while in storage at the center until shipment or disposal (where appropriate).
The sample receiver keeps full traceability of the samples while in storage and during use until 
used or disposed of or until further shipment and keeps documentation of receipt of arrival.
[COMPANY_008] will keep oversight of the entire life cycle through internal procedures, 
monitoring of study sites, auditing or process checks, and contractual requirements of external 
laboratory providers
Samples retained for further use will be stored in the AZ-assigned biobanks and will be 
registered by [CONTACT_230615].
C 2 Withdrawal of Informed Consent for donated biological samples
If a patient withdraws consent to the use of donated biological samples, the samples will be 
disposed of/destroyed, and the action documented. If samples are already analyzed, [COMPANY_008] is not obliged to destroy the results of this research.
The Investigator:
!Ensures patients‚Äô withdrawal of informed consent to the use of donated samples is 
notified immediately to [COMPANY_008]
!Ensures that biological samples from that patient, if stored at the study site, are 
immediately identified, disposed of /destroyed, and the action documented
!Ensures the organization(s) holding the samples is/are informed about the withdrawn 
consent immediately and that samples are disposed of/destroyed, the action documented and the signed document returned to the study site
!Ensures that the patient and [COMPANY_008] are informed a bout the sample disposal.
[COMPANY_008] ensures the organizations holding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of/destroyed and the action 
documented and returned to the study site.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 94 of 126C 3 International Airline Transportation Association (IATA) 6.[ADDRESS_277616] SAMPLES
International Airline Transportation Associatio n (IATA) classifies biohazardous agents into 3 
categories (http://www.iata.org/whatwedo/cargo/dangerous_goods/infectious_substances.htm) .For 
transport purposes the classification of infectious substances according to risk groups was removed from the Dangerous Goods Regulations in the 46th edition (2005). Infectious substances are now classified either as Category A, Category B or Exempt. There is no direct 
relationship between Risk Groups and Categories A and B.
Category A Infectious Substances are infectious substances in a form that, when exposure to 
it occurs, is capable of causing permanent di sability, life-threatening or fatal disease in 
otherwise healthy humans or animals. Category A pathogens are e.g., Ebola, Lassa fever 
virus:
!are to be packed and shipped in accordance with IATA Instruction 602.
Category B Infectious Substances are infectious Substances that do not meet the criteria for 
inclusion in Category A. Category B pathogens are e.g., Hepatitis A, B, C, D, and E viruses, Human immunodeficiency virus types 1 and 2. They are assigned the following UN number and proper shippi[INVESTIGATOR_72919]:
!UN 3373 ‚Äì Biological Substance, Category B
!are to be packed in accordance with UN3373 and IATA 650
Exempt - all other materials with minimal risk of containing pathogens
!Clinical trial samples will fall into Cate gory B or exempt under IATA regulations
!Clinical trial samples will routinely be packed and transported at ambient
!Temperature in IATA 650 compliant packaging
(http://www.iata.org/whatwedo/cargo/dangerous_goods/infectious_substances.htm)
!Biological samples transported in dry-ice require additional dangerous goods 
specification for the dry-ice content
!IATA compliant courier and packaging materials should be used for packing and 
transportation and packing s hould be done by [CONTACT_230616], as applicable
!Samples routinely transported by [CONTACT_230617] a safe and appropr iate way to contain 
any risk of infection or contamination by [CONTACT_73015]/containment materials at all times. The IATA [ADDRESS_277617] or rail transport is 
used.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 95 of 126Appendix D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 96 of 126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 97 of 126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 98 of 126 
 
 
 
 
 CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 99 of 126Appendix E Actions required in cases of increases in liver biochemistry 
and evaluation of Hy‚Äôs Law
E 1 Introduction
This Appendix describes the process to be followed in order to identify and appropriately 
report Potential Hy‚Äôs Law (PHL) cases and Hy‚Äôs Law (HL) cases. It is not intended to be a comprehensive guide to the managemen t of elevated liver biochemistries.
During the course of the study the Investigator will remain vigilant for increases in liver 
biochemistry. The Investigator is responsible for determining whether a patient meets PHL criteria at any point during the study.
All sources of laboratory data are appropriate for the determination of PHL and HL events; 
this includes samples taken at scheduled study visits and other visits including central and all local laboratory evaluations even if collected outside of the study visits; for example, PHL criteria could be met by [CONTACT_96724] a central laboratory and/or elevated total 
bilirubin (TBL) from a local laboratory.
The Investigator will also review Adverse Event (AE) data (for example, for AEs that may 
indicate elevations in liver biochemistry) for possible PHL events.
The Investigator participates, together with [COMPANY_008] clinical project representatives, in 
review and assessment of cases meeting PHL criteria to agree whether HL criteria are met. 
HL criteria are met if there is no alternati ve explanation for the elevations in liver 
biochemistry other than Drug Induced Liver Injury (DILI) caused by [CONTACT_7198] (IP).
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting Serious Adverse Events (SAEs) and AEs according to the outcome of the review and assessment in line with standard safety reporting processes.
E 2 Definitions
Potential Hy‚Äôs Law (PHL)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ‚â• 3√ó upper limit of 
normal (ULN) together with TBL‚â•2√óULN at any point during the study following the start 
of study medication irrespective of an increase in alkaline phosphatase (ALP).
Hy‚Äôs Law (HL)
AST or ALT ‚â•3√óU L N together with TBL‚â•2 √óULN, where no other reason, other than the 
IP, can be found to explain the combination of increases, e.g., elevated ALP indicating 
cholestasis, viral hepatitis, another drug.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277618] precede or be coincident with (i.e., on 
the same day) the elevation in TBL, but there is no specified time frame within which the 
elevations in transaminases and TBL must occur.
E 3 Identification of potential Hy‚Äôs Law cases
In order to identify cases of PHL it is important to perform a comprehensive review of 
laboratory data for any patient who meets any o f the following identification criteria in 
isolation or in combination:
!ALT ‚â• 3xULN
!AST ‚â•3xULN
!TBL ‚â•2xULN
Local laboratories being used:
The Investigator will with out delay rev iew each new la boratory report and if the identification 
criteria are met will:
!Determine whether the patient meets PHL criteria (see Section E 2Definitions within this 
Appendix for definition) by [CONTACT_230618]
!Promptly enter the laboratory data into the laboratory eCRF
E 4 Follow- up
E 4.1    Potential Hy‚Äôs Law criteria not met
If the patient does not meet PHL cr iteria the Investigator w ill:
!Perform follow-up on subsequent laboratory resu lts according to the guidance provided in 
the Clinical Study Protocol.
E 4.2    Potential Hy‚Äôs Law criteria met
If the patient does meet PHL cr iteria the Investigator w ill:
!Determine whether PHL criteria were met at any study visit prior to starting study 
treatment (See Section  E 6)
!Notify the [COMPANY_008] representative, who will then inform the central Study Team
!Within 1 day of PHL criteria being met, the Investigator will re port the case as an SAE of 
Potential Hy‚Äôs Law; serious criteria ‚ÄòImpor tant medical event‚Äô and causality assessment 
‚Äòyes/related‚Äô according to CSP process for SAE reporting.
!For patients who met PHL criteria prior to starting IP, the Investigator is not required to 
submit a PHL SAE unless there is a significant change#in the participant‚Äôs condition
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 101 of 126!The Study Physician contacts th e Investigator, to provide guidance, discuss and agree on 
an approach for the study patients‚Äô follow-up (including any further laboratory testing) 
and the continuous review of data.
!Subsequent to this contact [CONTACT_737] w ill:
‚àÄMonitor the patient until liver biochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically indicated
‚àÄInvestigate the etiology of the event and perform diagnostic investigations as 
discussed with the Study Physician. This includes deciding which the tests available 
in the Hy‚Äôs Law lab kit should be used
‚àÄComplete the 3 Liver eCRF Modules as i nformation becomes available
#A ‚Äòsignificant‚Äô change in the participant‚Äôs condition refers  to a clinically relevant change in 
any of the individual liver biochemistry parameters (ALT, AST or total bilirubin) in isolation or in combination, or a clinically relevant change in associated symptoms. The determination 
of whether there has been a significant change will be at the discretion of the Investigator; this 
may be in consultation with the Study Physician if there is any uncertainty.
E 5 Review and Assessment of Potential Hy‚Äôs Law cases
The instructions in this section should be followed for all cases where PHL criteria are met.
As soon as possible after the biochemistry abnormality was initially detected, the Study 
Physician contacts the Investigator in order to review available data and agree on whether 
there is an alternative explanation for meeting PHL criteria other than DILI caused by [CONTACT_33249], 
to ensure timely analysis and reporting to health authorities within [ADDRESS_277619] and TBL elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequently whether the AE meets the criteria for a SAE:
!If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate eCRF
!If the alternative explanation is an AE/SAE: update the previously submitted Potential 
Hy‚Äôs Law SAE and AE eCRFs accordingly with the new information (reassessing event term; causality and seriousness criteria) following the [COMPANY_008] standard processes.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277620] and TBL 
elevations other than the IP:
!Send updated SAE (report term ‚ÄòHy‚Äôs Law‚Äô) according to [COMPANY_008] standard 
processes.
‚àÄThe ‚ÄòMedically Important‚Äô serious criterion should be used if no other serious criteria 
apply
‚àÄAs there is no alternative explanation for the HL case, a causality assessment of 
‚Äòrelated‚Äô should be assigned.
If there is an unavoidable delay of over 15 calendar days in obtaining the information 
necessary to assess whether or not the case meets the criteria for HL, then it is assumed that there is no alternative explanation until such time as an informed decision can be made:
!Provide any further update to the previously submitted SAE of Potential Hy‚Äôs Law, 
(report term now ‚ÄòHy‚Äôs Law case‚Äô) ensuring causality assessment is related to IP and 
seriousness criteria is medically important, according to CSP process for SAE reporting.
!Continue follow-up and review according to agreed plan. Once the necessary 
supplementary information is obtained, repeat the review and assessment to determine whether HL criteria are met. Update the previously submi tted PHL SAE re port following 
CSP process for SAE reporting, according to the outcome of the review amending the 
reported term if an alternative explanation for the liver biochemistry elevations is 
determined.
E 6 Actions required when potential Hy‚Äôs Law criteria are met before 
and after starting study treatment
This section is applicable to patients with liver metastases who meet PHL criteria on study 
treatment having previously met PHL criteria at a s tudy visit prior to starting study treatment.
At the first on-study treatment occurrence of PHL criteria being met, the Investigator will 
determine if there has been a significant change in the patients‚Äô condition#compared with the 
last visit where PHL criteria were met.#
!If there is no significant change, no action is required
!If there is a significant change, notify the [COMPANY_008] representative, who will inform the 
central Study Team, then follow the s ubsequent process described in Section  E 4.2.
E 7 Actions required for repeat epi[INVESTIGATOR_72921]‚Äôs Law
This section is applicable when a patient meets PHL criteria on study tr eatment, and has 
already met PHL criteria at a previous on study treatment visit.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277621] follow-up, review, and assessment of a repeat occurrence(s) of 
PHL is based on the nature of the alternative cause identified for the previous occurrence.
The Investigator should d etermine the cause for the previous occurrence of PHL criteria being 
met and answer the following question:
Was the alternative cause for the previous o ccurrence of PHL cri teria bein g met found 
to be the disease under study (e.g., chroni c or progressing malignant disease, severe 
infection or liver disease), or did the patient meet PHL criteria prior to starting study treatment and at first on-study treatment visit, as described in Section  E 6 of this 
Appendix?
IfNo: Follow the process described in Section E 4.2 for reporting PHL as an SAE.
IfYes: Determine if there has been a significant
#change in the patient‚Äôs condition compared 
with when PHL criteria were previously met.
If there is no significant change, no action is required.
If there is a significant change, follow the process described in Section E 4.2 for reporting 
PHL as an SAE.
# A ‚Äòsignificant‚Äô change in the patient‚Äôs condition refers to a clinically relevant change in any 
of the individual liver biochemistry parameters ( ALT, AST or total bilirubin) in isolation or in 
combination, or a clinically relevant change in associated symptoms. The determination of whether there has been a significant change will be at the discretion of the Investigator; this 
may be in consultation with the Study Physician if there is any uncertainty.
E [ADDRESS_277622] results need to be recorded.
Hy‚Äôs Law lab kit for central laboratories
Additional standard chemistry and 
coagulation testsGGT 
LDHProthrombin timeINR
Viral hepatitis Immu noglobulin M (IgM) anti-HAV
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 104 of 126IgM and Immunoglobulin G (IgG) anti-
HBc
HBsAg 
HBV DNAaIgG anti-HCV 
HCV RNAa
IgM anti-HEV
HEV RNA
Other viral infections IgM & IgG anti-CMV 
IgM & IgG anti-HSV
IgM & IgG anti-EBV
Alcoholic hepatitis Ca rbohydrate deficient transferrin (CD-
transferrin)b
Autoimmune hepatitis Antinuclear anti body ( ANA)
Anti-Liver/Kidney Microsomal Ab (Anti-
LKM)
Anti-Smooth Muscle Ab (ASMA)
Metabolic diseases alpha-1-antitrypsin 
Ceruloplasmin
IronFerritin 
Transferrin
b
Transferrin saturation
aHCV RNA is only tested when IgG anti-HCV is positive or inconclusive
bCD-transferrin and Transferrin are not availab le in China. Study teams should amend this list accordingly
E 9 References
Aithal et al, 2011
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al 2011. Case 
definition and phenotype standardization in drug-induced liver injury. Clin Pharm Ther.
2011;89(6):806-15.
FDA Guidance for Industry July 2009
FDA Guidance for Industry (issued July 2009) ‚ÄòD rug-induced liver injury: Premarketing 
clinical evaluation‚Äô Available from; https://www.fda.gov/regulatory-informati on/search- fda-
guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 105 of 126Appendix F Abreviations
Abbreviation Explanation
A2AR Adenosine 2a receptor
ADA Anti-drug antibody
AE Adverse event (see definition in Appendix B)
AESI Adverse event of special interest
ALP Alkaline phosphatase
ALT Alanine aminotransferase
AST Aspartate aminotransferase
AUC Area under the con centration- time c urve
BCRP Breast cancer resistance protein
BP Blood pressure
CD73 Cluster of differentiation 73: 5'-nucleotidase (5'-NT) or ecto-5'-nucleotidase
CI Confidence interval
Cmax Maximum observed concentration
CNS Central nervous system
CR Complete response
CRP C-reactive pro tein
CSR Clinical study re port
CT Computed tomography
CTCAE Common Terminology Criteria for Adverse Events
CYP Cytochrome P450
DCO Data cut-off
DILI Drug induced liver injury
DLT Dose-limiting toxicity
ECG Electrocardiogram
ECHO Echocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF Electronic case report form
EGFR Epi[INVESTIGATOR_230567] (visit)
FDA Food and Drug Administration
FDG-PET Fluorodeoxyglucose positron emission tomography
FTIH First-time-in-human
GCP Good Clinical Pr acticeCCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 106 of 126Abbreviation Explanation
GGT Gamma glu tamyltransferase
HL Hy‚Äôs Law
IATA International Air Transport Association
IB Investigator‚Äôs brochure
IC50 Concentration giving 50% of the drug-induced inhibitory effect
ICF Informed consent form
ICH International Council for Harmonis ation
IEC Independent ethics co mmittee
ILD Interstitial lung disease
imAE Immune-mediated adverse event
IP Investigati onal product
IRB Institutional Review Board
IV Intravenous
IWRS Interactive web response system
LDH Lactate de hydrogenase
mAb Monoclonal antibody
MATE1 Multi-drug and toxin extrusion protein 1
mCRPC Metastatic castration-resistant prostate carcinoma
MDSC Myeloid-derived s uppressor cells
MOA Mechanism of action
MRI Magnetic resonance imaging
MTD Maximum-tolerated dose
MUGA Multi-g ated acquisition scan
NCI National Cancer Ins titute
NE Not evaluable
NHA New hormonal agent(s)
NSCLC Non-small cell lung cancer
NTL Non-target lesion
OAT1 Organic anion transporter [ADDRESS_277623] Organic catio n transporter
ORR Overall response rateCCI
CCI
CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 107 of 126Abbreviation Explanation
PBMC Peripheral blood mononuclear cells
PCWG3 Prostate Cancer Working Group 3
PD Progression of disease
PD-1 Programmed cell death protein 1 (e.g., nivolumab [Opdivo¬Æ])
PD-L1 Programmed death ligand 1
PDx Pharmacodynamics
PET Positron emission tomography
PFS Progression-free survival
P-gp P-glycoprotein
PHL Potential Hy‚Äôs Law
PK Pharmacokinetics
PO Per os (orally)
PR Partial res ponse
PSA Prostate-specific antigen
Q2W Every 2 weeks
Q4W Every 4 weeks
QD Once daily
QRS QRS complex; the main spi[INVESTIGATOR_230568] T wave
QTc QT interval corrected for heart rate
QtcF QT interval corrected for heart rate using Fridericia‚Äôs formula
RECIST Response Evaluation Criteria in Solid Tumors
RP2D Recommended Phase 2 dose
rPFS Radiographic progression-free s urvival
SAE Serious adverse event (see definition in Appendix B)
SD Stable disease
SoA Schedule of activities
SRC Safety Review Committee
TBL Total bilirubin
TBNK Complete immune panel (T-, B-, and n atural killer [NK] lymphocyte subsets)
TL Target lesion
tmax Time to reach C max
TME Tumor microenvironment
ULN Upper limit of normalCCI
Clinical Study Protocol ‚Äì 8.[ADDRESS_277624] Version 1.1 (Response Evaluation Criteria in Solid Tumors) in Soft Tissue and PCWG3 (Prostate Cancer Working Group Criteria 3) in Bone Lesions
INTRODUCTION
This appendix details the implementation of RECIST (Response Evaluation Criteria in Solid 
Tumors) 1.1 guidelines (Eisenhauer et al. 2009) and PCWG3 guidelines (Scher et al. 2016) for 
the D8731C00001 study with regards to Investigator assessment of tumor burden including protocol-specific requirements for this study.
ASSESSMENT OF SOFT TISSUE DISEASE USING RECIST 1.[ADDRESS_277625] one lesion (measurable and/or non-measurable) that can be accurately 
assessed at baseline by [CONTACT_20420] (CT), magnetic resonance imaging (MRI) or plain X-ray should be included in this study.
Measurable:A lesion, not previously irradiated, that can be accurately measured at baseline as ‚â•[ADDRESS_277626] diameter (except lymph nodes which must have short axis ‚â• 15 mm) with 
computed tomography (CT) or magnetic resona nce imaging (MRI) and which is suitable for 
accurate repeated measurements.
Non-measurable:
!All other lesions, including small lesions (longest diameter <10 mm or pathological 
lymph nodes with ‚â•10 to <15mm short axis at baseline*).
!Truly non-measurable lesions include the following: leptomeningeal disease, ascites, 
pleural / pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal masses/abdominal organomegaly identified by [CONTACT_230619].
!Previously irradiated lesions**.
!Skin lesions
!Brain metastasis
*Nodes with <10mm short axis are considered non-pathological and should not be recorded or 
followed as NTL.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 109 of 126**Localized post-radiation changes which affect lesion sizes may occur. Therefore, lesions 
that have been previously irradiated will not be considered measurabl e and must be selected as 
Non-Target Lesions (NTL) at baseline and followed up as part of the NTL assessment.
Special Cases:
!Lytic bone lesions or mixed lytic blastic lesions, with identifiable soft tissue components, 
can be considered measurable if the soft tissue component meets the definition of 
measurability. Blastic lesions are considered non-measurable.
!Cystic metastases can be considered measurable lesions if they meet the criteria for 
measurability from a radiological point of view, but if non-cystic lesions are present in the 
same subject, these should be selected as target lesions.
Target lesions:
A maximum of 5 measurable lesions (with a maximum of 2 lesions per organ), representative 
of all lesions involved suitable for accurate repeated measurement, should be identified as 
target lesions (TL) at baseline.
Non-Target lesions:
All other lesions (or sites of disease) not recorded as TL should be identified as NTL at 
baseline (except bone lesions which will be assessed as defined in bone lesion s ection of this 
appendix).
Methods of assessment
The same method of assessment and the same technique should be used to characterize 
each identified and recorded lesion at baseline and during follow-up visits.
A summary of the methods to be used for RECIST assessment is provided below and those 
excluded from tumor assessments for this study are highlighted, with the rationale provided.
Table [ADDRESS_277627] (preferred) 
MRICT (preferred) 
MRIX-ray, Chest X-rayCT (preferred) 
MRIX-ray, Chest X-ray 
UltrasoundFDG-PET
Clinical Study Protocol ‚Äì 8.[ADDRESS_277628] examination with intravenous (i.v.) contrast media administration is the preferred method. MRI should be used where CT is not feasible or it is medically contra-indicated.
Every effort s hould be made to maintain the radiologic imaging modality used at baseline 
throughout subsequent assessments.
X-raysPlain X-raysPlain X-rays may be used as a method of assessment for bone NTLs and to identify the 
presence of new bone lesions.
Chest X-ray
In the D8731C00001 study, chest X-ray assessment will not be used for assessment of TL as 
they will be assessed by [CONTACT_76481]. Chest X-ray can, however, be 
used to assess NTL and to identify the presence of new lesions.
Ultrasound
In the D8731C00001 study, ultrasound examination will not be used for assessment of TL and 
NTL as it is not a reproducible method, does not provide an accurate assessment of tumor size and it is subjective and operator dependent. Ultrasound examination can, however, be used to identify the presence of new lesions. If new c linical symptoms occur and an ultrasound is 
performed then new lesions should be confirmed by [CONTACT_76482].
Endoscopy and laparoscopyIn the D8731C00001 study, endoscopy and laparoscopy will not be used for tumor 
assessments as they are not validated in the context of tumor assessment.
 
CCI
Clinical Study Protocol ‚Äì 8.[ADDRESS_277629] 1.1 and tumor response assessments will be performed on radiological criteria only.
FDG-PET scan
In the D8731C00001 study FDG-PET scans may be used as a method for identifying new 
lesions, according with the following algorithm: New lesions will be recorded where there is positive FDG uptake* not present on baseline FDG-PET scan or in a location corresponding to a new lesion on CT/MRI at the same follow-up visit. If there is no baseline FDG-PET scan available, and no evidence of new lesions on CT/MRI scans then follow-up CT/MRI assessments should be continued, scheduled as per protocol or clinical indicated, in order to 
confirm new lesions.
* A positive FDG-PET scan lesion should be reported only when an uptake greater than twice 
that of the surrounding tissue is observed.
Tumor response evaluation
Schedule of evaluation
Baseline assessments should encompass all areas of known predilection for metastases in the 
disease under evaluation and s hould additionally investigate areas that may be involved based 
on signs and symptoms of individual subjects and should be performed no more than 28 days before allocation/ra ndomization. The first follow-up assessment for Modules 1, 2, and 3 
should be initially at 6 weeks (¬±1 wee k) following the start of AZD4635 dosing and 
subsequent assessments will be performed ever y 2 cycles (8 weeks, ¬±1 week) thereafter. Any 
other sites at which new disease is suspected should also be adequately imaged at follow-up.
If an unscheduled assessment was performed and the subject has not progressed, every 
attempt should be made to perform the subsequent  assessments at their originally scheduled 
visits. This schedule is to be followed in order to minimize any unintentional bias caused by [CONTACT_230620] a different frequency than other subjects.
Target lesions (TL) 
Documentation of target lesions
A maximum of 5 measurable lesions, with a maximum of 2 lesions per organ (including 
lymph nodes), representative of all lesions involved should be identified as TL at baseline.CCI
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 112 of 126Target lesions should be s elected on the basis of their size (longest diameter for non-nodal 
lesions or short axis for nodal lesions), but in addition should be those that lend themselves to 
reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement in which circumstance the next largest lesion, which can be measured reproducibly, should be selected.
The site and lo cation of each TL should be documented as well as the longest diameter for 
non-nodal lesions (or short axis for lymph nodes). All measurements should be recorded in millimeters. At baseline the sum of the diameters for all TL will be calculated and reported as 
the baseline sum of diameters. At follow-up visits the sum of diameters for all TL will be calculated and reported as the follow-up sum of diameters.
Special cases:
!For TL measurable in [ADDRESS_277630] diameter. For
pathological lymph nodes measurable in 2 or 3 dimensions, always report the short axis.
!If the CT/MRI slice thickness used is > 5mm, the minimum size of measurable disease at 
baseline should be twice the slice thickness of the baseline scan.
!If a lesion has completely disappeared, the longest diameter should be recorded as 0 mm.
!If a TL splits into [ADDRESS_277631] the sum of the di ameters of those parts.
!If 2 or more TL merge then the sum of the diameters of the combined lesion should be 
recorded for one of the lesions and 0 mm recorded for the other lesion(s).
!If a TL is believed to be present and is fa intly seen but too small to measure, a default 
value of 5mm should be assigned. If an accurate measure can be given, this should be 
recorded, even if it is below 5mm.
!If a TL cannot be measured acc urately due to it being too la rge, provide an estimate of the 
size of the lesion.
!When a TL has had any intervention e.g., radiotherapy, embo lization, s urgery etc., during 
the study, the size of the TL should st ill be provided where possible.
Evaluation of target lesions
This section provides the definitions of the criteria used to d etermine obj ective tumor visit 
response for TL.
Table 12 Evaluation of target lesions
Complete Response (CR) Disappearance of all target lesions since baseline. Any patholog ical
lymph nodes selected as target lesions must have a reduction in short 
axis to < 10 mm.
Partial Response (PR) At least a 30% decrease in the sum of the diameters of TL, taking as
reference the baseline sum of diameters
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 113 of 126Table 12 Evaluation of target lesions
Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to
qualify for PD
Progressive Disease (PD) At least a 20% increase in the sum of diameters of target lesions, taking
as reference the smallest sum on study (this includes the baseline sum if 
that is the smallest on study). In add ition to the relative increase of 20%, 
the sum must also demonstrate an absolute increase of at least 5 mm.
Not Evaluable (NE) Only relevant if any of the target lesions were not assessed or not
evaluable or had a lesion intervention at this visit. Note: If the sum of 
diameters meets the progressive disease criteria, progressive disease 
overrides not evaluable as a target lesion response
Non-Target lesions (NTL) 
Evaluation of non-target lesions
All other lesions (or sites of disease), except for bone lesions, not recorded as TL should be 
identified as NTL at baseline. Measurements are not required for these lesions, but their status should be followed at subsequent visits. At each visit an overall assessment of the NTL response should be recorded by [CONTACT_148606]. This section provides the definitions of the 
criteria used to determine and record overall response for NTL at the investigational site at each visit.
Table 13 Evaluation of Non-Target Lesions
Complete Response (CR) Disappearance of all non-target lesions since baseline. All lymph nodes
must be non-pathological in size (< 10 mm short axis).
Non CR/Non PD Persistence of one or more NTLProgression (PD) Unequivocal progression of existing non-target lesions. Unequivocal
progression may be due to an important progression in one lesion only or in several lesions. In all cases the progression MUST be clinically 
significant for the physician to consider changing (or stoppi[INVESTIGATOR_007]) therapy.
Not Evaluable (NE) Only relevant when one or some of the non-target lesions were not
assessed and, in the Investigator's opi[INVESTIGATOR_1649], they are not able to provide an evaluable overall non-target lesion assessment at this visit.
Note: For subjects without target lesions at baseline, this is relevant if 
any of the non-target lesions were not assessed at this visit and the 
progression criteria have not been met.
To achieve ‚Äòunequivocal progression‚Äô on the basis of non-target lesions, there must be an 
overall level of substantial worsening in non-target disease such that, even in presence of SD or PR in target lesions, the overall tumor burden has increased sufficiently to merit
Clinical Study Protocol ‚Äì 8.[ADDRESS_277632] ‚Äòincrease‚Äô in the size of one or more non-target lesions 
is usually not sufficient to qualify for unequivocal progression status.
New LesionsDetails of any new soft tissue lesions will also be recorded with the date of assessment. The 
presence of one or more new lesions is assessed as progression.
A lesion identified at a follow-up assessment in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression.
The finding of a new lesion should be unequivocal: i.e., not attributable to differences in 
scanning technique, change in imaging modality or f indings thought to represent something 
other than tumor.
If a new lesion is equivocal, for example because of its small size, the treatment and tumor 
assessments should be continued until the new lesion has been confirmed. If repeat scans confirm there is a new lesion, then the progressi on date should b e declared using the date of 
the initial scan.
Symptomatic deterioration
Symptomatic deterioration is not a descriptor of an objective response; it is a reason for 
stoppi[INVESTIGATOR_12003].
Evaluation of Overall Visit Soft Tissue ResponseThe overall visit response will be de rived using the algorithm shown in Table 14.
Table 14 Overall Visit Soft Tissue Response
Target lesions Non-Target lesions New Lesions Overall soft tissue response
CR CR No CR
CR NA No CR
NA CR No CR
CR Non CR/Non PD No PR
CR NE No PR
PR Non PD or NE No PR
SD Non PD or NE No SD
NA Non CR/Non PD No SD (Non CR/Non PD)
NA NA No NED
NE Non PD or NE No NE
NA NE No NE
PD Any Yes or No PD
Any PD Yes or No PDAny Any Yes PD
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 115 of 126CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NE = not 
evaluable, NA = not applicable (only relevant if there were no TL and/or NTLs at baseline), NED = No Evidence 
of Disease (only relevant when there is no TL and NTL from baseline).
Specifications for radiological imaging
These notes are recommendations for use in clinical studies. The use of standardized 
protocols for CT and MRI allows comparability both within and between different studies, 
irrespective of where the examination has been undertaken.
CT scan
CT scans of the chest, abdomen, and pelvis should be conti guous throughout all the 
anatomical regions of interest.
The most critical CT image acquisition pa rameters for optimal tumor evaluation using 
RECIST Version 1.[ADDRESS_277633] administration
Optimal visualization and measurement of metastases in solid tumors requires consistent 
administration (dose and rate) of intravenous contrast as well as timing of scanning.
Typi[INVESTIGATOR_897], most abdominal imaging is performed during the portal venous phase and 
(optimally) about the same time frame after in jection on each examination. An adequate 
volume of a suitable contrast agent should be given so that the metastases are demonstr ated to 
best effect and a consistent method is used on subsequent examinations for any given patient. It is very important that the same technique be used at baseline and on follow- up examinations for a given patient. For patients who develop contraindications to contrast after 
baseline contrast CT is done, the decision as to whether non-contrast CT or MRI (enhanced or non-enhanced) should be performed should also be based on the tumor type and anatomic location of the disease and should be optimized to allow for comparison to the prior studies if 
possible. Each case should be discussed with the radiologist to determine if substitution of 
these other approaches is possible and, if not, the patient should be considered not evaluable from that point forward. Care must be taken in measurement of TLs on a different modality
Clinical Study Protocol ‚Äì 8.[ADDRESS_277634] scans be performed at 5 mm contiguous slice thickness and this 
guideline presumes a minimum 5 mm thickness in recommendations for the measurable lesion definition. Exceptionally, particular institutions may perform medically acceptable scans at slice thicknesses greater than 5 mm. If this occurs, the minimum size of measurable lesions at baseline should be twice the slice thickness of the baseline scans.
All window settings should be included in the assessment, particularly in the thorax where 
lung and soft tissue windows should be considered. When measuring lesions, the TLs should be measured on the same wi ndow setting for repeated examinations throughout the study. All 
images from each examination should be included in the assessment and not ‚Äúselected‚Äù images of the apparent lesion.
MRI scan
MRI has excellent contrast, spatial and temporal resolution; however, there are many image 
acquisition variables involved in MRI, which greatly impact image quality, lesion conspi[INVESTIGATOR_230569]. Furthermore, the availability of MRI is variable globally. The modality used at follow-up s hould be the same as was used at baseline and the lesions should be 
measured/assessed on the same pulse sequence. Generally, axial imaging of the abdomen and pelvis with T1 and T2 weighted imaging along with gadolinium-enhanced imaging should be 
performed. The field of view, matrix, number of excitations, phase encode steps, use of fat 
suppression and fast sequences s hould be optimized for the sp ecific body part being imaged as 
well as the scanner utilized. It is beyond the scope of this appendix to prescribe specific MRI pulse sequence parameters for all scanners, body parts and diseases. Ideally, the same type of scanner should be used and the image acquisiti on protocol should be followed as closely as 
possible to prior scans. Body scans should be performed with breath-hold scanning 
techniques if possible.
For these reasons, CT is the imaging modality of choice.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277635] in jection. PET camera specifications are variable 
and manufacturer specific, so ever y attempt should be made to use the same scanner, or the 
same model scanner, for serial scans on the s ame patient. Whole-body acquisitions can be 
performed in either 2- or 3-d imensional mode wi th attenuation correction, but the met hod 
chosen should be consistent across all patien ts and serial scans in the clinical study.
PET/CT scans
At present, low dose or attenuation correction CT portions of a combined PET/CT are of 
limited use in anatomically based efficacy assessments and it is therefore suggested that they 
should not be substituted for dedicated diagnostic contrast enhanced CT scans for tumor measurements by [CONTACT_150114] 1.1. In exceptional situations, if a site can document that the CT performed as part of a PET/CT is of identical diagnostic quality to a diagnostic CT 
(with IV and oral contrast) then the CT portion of the PET/CT can be used for RECIST measurements. However, this is not recommended because the PET portion of the CT 
introduces additional data that may bias an Investigator if it is not routinely or serially 
performed.
ASSESSMENT OF BONE LESION PROGRESSION USING PCWG3 
CRITERIA
Bone lesions will be assessed by [CONTACT_230621] v1.[ADDRESS_277636] the new lesion.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277637] follow-up assessment for Modu les 1, 2, and 3 should be initially at 6 
weeks (¬±1 week) following the start of AZD4635 dosing and subsequent assessments will be performed every 2 cycles (8 weeks, ¬±1 week) thereafter.
If an unscheduled assessment was performed and the subject has not progressed, every 
attempt should be made to perform the subsequent  assessments at their originally scheduled 
visits. This schedule is to be followed in order to minimize any unintentional bias caused by [CONTACT_230620] a different frequency than other subjects.
Documentation of lesions
All bone lesions (or sites of di sease) should be identified by a bone scan at baseline. Their 
status should be followed at subsequent visits. At each visit an overall a ssessment of the bone 
lesion progression should be recorded by [CONTACT_737]. This section provides the definitions of the criteria used to determine and record bone progression at the investigational site at each visit.
Progression on a bone scan is identified using PCWG3 as follows:
!At the first bone scan post-baseline (6 weeks):
[ADDRESS_277638] 6 weeks later and 
preferably no later than the next scheduled  visit for a bone scan (i.e., Week 12), must 
show 2 or more additional new metastatic bone lesions (for a total of 4 or more new 
metastatic bone lesions since the baseline assessment) for progression to be documented.
Note - The first bone scan completed after baseline will be considered the ‚Äò6-week scan‚Äô 
regardless if taken at week 6 or at an unscheduled assessment.
!After the first bone scan post-baseline (6 weeks):
2 or more new metastatic bone lesions are observed compared to the 6 ‚Äëweek assessment. 
The confirmatory scan, performed at least [ADDRESS_277639] documents the second lesion.
Evaluation of bone progression status
Table 15 provides the definitions for the visit bone progression s tatus for bone lesions.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 119 of 126Table 15 Bone progression status
Non Progressive Disease (Non-PD) No evidence of progression, or appearance of one new bone lesion, or
non-fulfillment of the progression criteria including new lesions without 
confirmation of progression.
Progressive Disease (PD) Bone lesions fulfilling the requirements for at least 2 new lesions and 
confirmation of progression.
Not Evaluable (NE) Only relevant if a follow-up bone scan is not pe rformed
OVERALL RADIOLOGICAL VISIT ASSESSMENT
Table 16 provides the definitions how the visit responses for soft tissue (according to 
RECIST1.1 criteria) and bone progression status ( according to PCWG3 criteria) are combined 
to give an overall radiological objective visit response.
Table 16 Overall radiological visit response
Overall visit soft tissue 
response (RECIST 1.1)Bone progression status 
(PCWG3)Bone lesions at visit 
Present/AbsentOverall radiological 
visit response
CR Non-PD Absent CR
CR Non-PD Present PR
CR NE - PRPR Non-PD or NE Any PR
SD Non-PD or NE Any SD
NED Non-PD or NE Any Non-PD
NE Non-PD or NE Any NE
PD Any Any PDAny PD Any PD
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NE = not 
evaluable, NED = No Evidence of Disease (only relevant when there is no TL and NTL from baseline).
CONFIRMATION OF RESPONSE
In the D8731C00001 study, imaging for confirmation of response (CR or PR) should be 
performed at the next scheduled RECIST and PCWG3 assessment, i.e., 8 weeks (and must not be less than 4 weeks later) following the date the criteria for response were first met.
Clinical Study Protocol ‚Äì 8.[ADDRESS_277640] Overall response
CR CR CR
CR PR SD, PD or PRa
CR SD SD or PD
CR PD SD or PD
CR NE SD or NE
PR CR PR
PR PR PRPR SD SD
PR PD SD or PD
PR NE SD or NENE NE NE
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NE = not 
evaluable.
aIf a CR is truly met at first time point, then any diseas e seen at subsequent time point, even disease meeting 
PR criteria relative to baseline, makes the disease PD at tha t point (since disease must have reappeared after 
CR). Best response would depend on whether minimum duration for SD was met. However, sometimes 
‚ÄòCR‚Äô may be claimed when subsequent scan suggest small lesions were likely still present and in fact the subject had PR, not CR at the first time point. Under these circumstances, the original CR should be changed to PR and the best response is PR.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 124 of 126Appendix I PCWG 3 PSA Criteria
Baseline/Study Entry
PSA progression requirements for study entry
Patients must have measurable PSA ‚â•1.0 ng/mL as the minimum starting level for trial entry 
if the confirmed rise is the only indication of progression (excluding pure small cell carcinoma). It is recommended to estimate a pre-treatment PSA doubling time (PSADT) if at least 3 values are available ‚â•4 weeks apart. Treatment or enrollment onto a trial s hould not be 
delayed to estimate PSADT.
On-Study Disease Assessments
!PSA results are to be collected on Day 1 of each treatment cycle
‚àÄContinue through early rises for a minimum of 12 weeks unless there is other 
evidence of progression, as a favorable effects on PSA may be delayed for ‚â•12 weeks
‚àÄIgnore PSA rises before 12 weeks in determining PSA response
Patients with PSA progression are allowed a nd encouraged to continue treatment un til 
symptomatic or radiographic progression.
Reference: Scher et al. 2016
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 125 of 126Appendix J Disallowed medications
Contribution of CYP1A2 to AZD4635 metabolism appears to be >80%. The following 
CYP1A2 strong and moderate inducers and inhibitors (Table 19) are not permitted from [ADDRESS_277641] dose of AZD4635.
Table 19 Examples of CYP1A2 inhibitors and inducers of
CYP1A2 Strong inhibitors Moderate inhibitors
Ciprofloxacin, clinafloxacin, enoxacin, 
fluvoxamine(a), oltipraz, zafirlukast, 
rofecoxib, Angelica root - Bai Zhi (Angelica dahurica radix)Methoxsalen, mexiletine ,oral 
contraceptives,3,4-methylene-dioxymethamphetamine (MDMA), etintidine, genistein, idrocilamide, 
osilodrostat, phenylpropanolamine, 
pi[INVESTIGATOR_230570], propafenone, propranolol, troleandomycin, vemurafenib, grepafloxacin, pi[INVESTIGATOR_5329], zileuton
Strong Inducers Moderate Inducers
Phenytoin, rifampin, ritonavir, smoking, teriflunomide
aStrong inhibitor of CYP1A2 and CYP2C19, and moderate inhibitor of CYP2D6 and CYP3A.
Use of inhibitors or inducers of BCRP and sen sitive substrates of OATP1B1/3, OAT1, OCT1, 
OCT2, MATE1 and P-gp is not permitted from [ADDRESS_277642] dose of AZD4635.
Examples of sensitive substrates of th ese substrates above are presented in Table 20.
Information on any treatment in the 4 weeks prior to starting study treatment and all 
concomitant treatments given during the study with reasons for the treatment should be recorded. If medically feasible, patients taking regular medication, with the exception of examples of known substrates of transporters listed in Table 20, should be maintained on it 
throughout the study period.
Clinical Study Protocol ‚Äì 8.0 
AZD4635 - D8731C00001[COMPANY_008] 
Core Clinical Study Protocol
CONFIDENTIAL AND PROPRIETARY 126 of 126Table 20 Examples of substrates of transporters
Substrate category Examples of drugs in the category
Sensitive substrates of:
BCRP Methotrexate, mitoxantrone, imatinib, lapatinib, sulfasalazine, 
topotecan, daunorubicin, doxorubicin, SN-38, irinotecan, prazosin, pantoprazole, atorvastatin, fluvastatin, rosuvastatin, simvastatin.
OAT1 Adefovir, captopril, furosemide, lamivudine, methotrexate, 
oseltamivir, tenofovir, zalcitabine, zidovudine, ciprofloxacin, cephaloridine, methotrexate, pravastatin
OATP1B1, OATP1B3 Asunaprevir, atorvastatin, bosentan, danoprevir, docetaxel, 
fexofenadine, glyburide, nateglinide, paclitaxel, pi[INVESTIGATOR_2830], pravastatin, repaglinide, rosuvastatin, simvastatin acid
OCT1 Metformin, oxaliplatin, aciclovir, gan ciclovir
OCT2 Metformin, pi[INVESTIGATOR_8405], procainamide, ranitidine 
amantadine, amiloride, oxaliplatin, varenicline, cisplastin, debrisoquine, propranolol, guanidine, D-tubocurarine,
pancuronium,
memantine, pi[INVESTIGATOR_14958], ifosfamide, cimetidine, famotidine, 
zalcitabine, lamivudine, berberine
MATE1 Metformin
P-gp Dabigatran etexilate, digoxin, fe xofenadine
SIGNATURE [CONTACT_73032] a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic signature
[CONTACT_24558]: d8731c00001-csp-v8
Document Title: D8731C00001 Clinical Study Protocol version 8
Document ID:
Version Label: 10.[ADDRESS_277643] APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‚ÄòUTC‚ÄôZ)Signed by [CONTACT_24557]
03-Oct-2022 16:[ADDRESS_277644]-2022 01:[ADDRESS_277645]-2022 08:32 UTC Content Approval[COMPANY_003]
[COMPANY_003]
[COMPANY_003]CCI
CCI